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^ Abstract 
Osteoporosis is as old as the origin of human civilization yet complete 
understanding about it remains to be achieved till date. Osteoporosis and 
associated fractures constitute a major public health issue together 
representing an important cause of mortality and morbidity with annual 
incidence of fracture rates exceeding the combined incidence of breast 
cancer, stroke and heart attacks in postmenopausal women (PMW). 
Emergence of osteoporosis as a global bone health concern is reflected in the 
occurrence of 1.6 million hip fractures annually worldwide and the number 
projected to go up four times by 2050. Though osteoporosis affects both men 
and women, the later are more susceptible targets of this crippling bone 
disorder. 
It is long been recognized that infection, inflammation, and autoimmune 
disorders are associated with systemic and local bone loss. Yet, it is only 
recent that T lymphocytes and their product have been recognized as key 
regulators of bone cell formation, lifespan and activity. Of many 
proinflammatory cytokines activated in postmenopausal osteoporosis, TNF-a 
is probably the dominant cytokine, which promotes osteoclastogenesis by 
augmenting the production of RANKL, the non-redundant cytokine 
responsible for osteoclast development. This ability of TNF-a is due to 
synergistic interactions at the level of NF-KB and activator protein-1 (AP-1) 
signaling. Furthermore, TNF stimulates osteoclast (OC) activity and inhibits 
osteoblastogenesis thus further driving an imbalance between bone fonnation 
and bone resorption. 
With ever increasing number of elderly people in the population, improved 
survival and an increase in the age-specific fracture rates, there is an 
immediate need to develop new cost-effective therapeutic strategies against 
postmenopausal osteoporosis. In view of reactive oxygen species (ROS) and 
reactive nitrogen species (RNI) playing an important role in both estrogens 
related and unrelated osteoporosis, thus, greater emphasis is now being laid 
on development of compounds from natural sources having antioxidant and 
anti-inflammatory properties in combating osteoporosis. Earlier work in our 
laboratory has proved the antioxidant and anti-inflammatory effects of allicin 
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from garlic in other diseases. Thus, we studied the incorporation of such 
compounds like allicin from garlic, and neem extract as natural herbal 
treatment for estrogen - related / unrelated deficiency bone loss. 
The initial phase of the present study undertook a detailed characterization of 
sera and monocytes of postmenopausal patients to assess the activity of 
predominant antioxidant enzyme, GPx and to measure the intramonocyte 
(GSH) levels. Glutathione (GSH) directly reacts with ROS, and glutathione 
peroxidase (GPx) catalyses the removal of hydrogen peroxide. ELISA results 
showed almost less than half the activity of enzyme both in sera and 
monocytes of postmenopausal patients as compared to premenopausal non-
porotic (Pre-M-NP) healthy individuals. Decrease in GPx activity therefore, 
indicates impairment of hydrogen peroxide-neutralizing mechanism. A similar 
suppression in intramonocyte GSH levels was observed in these patients 
indicative of weak antioxidant power. The presence of elevated free radicals 
in postmenopausal patients was also substantiated by MDA determination. 
Considerable evidence has accumulated that suggests that estrogen prevents 
bone loss by blocking the production of proinflammatory cytokines by bone 
marrow stromal and bone cells. Cytokines regulated by estrogen are IL-1, IL-6 
and TNF a. In our study also, estimation by ELISA showed an appreciable 
secretion of TNF-a and IL-ip in the sera and monocytes of postmenopausal 
patients. Infact, IL-1 is a potent stimulator of bone resorption together with 
TNF, and both are well-recognized inhibitors of bone formation. IL-1 and TNF 
are also powerful inducers of other cytokines such as IL-6, M-CSF and GM-
CSF, which potentiate the effect of IL-1 on osteoclastogenesis. 
Next, an attempt was also made to characterize monocytes from 
postmenopausal patients with respect to TNF-a and osteoprotegrin (OPG). 
Monocytes from these patients were subjected to TNF-a and OPG mRNA 
evaluation by real-time RT-PCR revealing appreciably high basal levels of 
both mRNA expressions. 
Osteoporosis represents a polygenic disorder largely modified by a variety of 
factors, which include hormones and their receptors, cytokines and growth 
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factors, BMPs, and others. While RANKL is necessary for osteoclast 
differentiation, role of OPG in the pathogenesis of osteoporosis has not been 
clear since OPG levels are not consistently altered. In humans, OPG levels 
increasing with age are understood as a homeostatic response to limit the 
bone loss that occurs with an increase in other bone resorbing factors. Thus, 
in the present study, we attempted to probe the expression level of OPG 
together with TNF a and their regulation by natural antioxidants like allicin 
from garlic and neem extract in postmenopausal osteoporosis. 
Real-time RT-PCR data show that allicin down-regulated the expression of 
TNF-a and OPG mRNA in PBMC's of postmenopausal patients in a dose-
dependent manner. Concentrations of 250 and 500 ngs/ml of allicin were 
found to suppress the appreciably high basal levels of TNF and OPG mRNA's 
by ~5 and 6 logs respectively. It is to be pointed out that previous reports 
indicated higher doses of allicin were toxic to human cells. However, our 
laboratory has shown lower doses to be non-toxic and proved to be potent 
anti-inflammatory agent in other disease conditions such as tuberculosis. 
From our data, it is evident that whereas low concentrations of allicin used in 
this study appreciably down-regulate the mRNA expression of TNF a and 
OPG, at the same time show no significant effect on the expression of human 
housekeeping gene R18. Thus, low dose of allicin used in the study was non-
toxic. 
Similarly, real-time RT-PCR data show that neem extract also down-regulated 
the expression of TNF-a and OPG mRNA in PBMCs of postmenopausal 
patients in a dose-dependent manner. An appreciable suppression of TNF-a 
mRNA by ~5 and 6 logs and of OPG mRNA by ~4 and 6 logs were recorded 
at 250 and 500 pg/ml neem extract respectively. 
Thus, although OPG is produced in many tissues, bone derived OPG may be 
released into circulation, thereby reflecting the situation locally in bone. Our 
results showing increased OPG mRNA expression in the postmenopausal 
patient PBMC's therefore may indicate a compensatory response to increased 
osteoclastic bone resorption and the resultant bone loss caused by estrogen 
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deficiency; this considering the fact that OPG has bone sparing activity. The 
expression of OPG mRNA correlated positively with that of TNF a mRNA 
expression. Therefore, OPG, a soluble menriber of TNFR super family of 
proteins plays an important role in the negative regulation of osteoclastic bone 
resorption. 
Next, the levels of malondialdehyde (MDA), a by-product of lipid peroxidation 
were observed to be appreciably high both in sera and monocyte cultures of 
postmenopausal patients further pointing to the increased oxidant stress in 
such women. Subsequent increase in hydrogen peroxide levels due to 
depressed GSH levels and GPx activity in postmenopausal patients might 
have induced the peroxidation of polyunsaturated fatty acids, thereby leading 
to the formation of high MDA levels. Moreover, due to high reactivity of MDA 
towards amino groups may also lead to deactivation of enzymes. Allicin and 
neem extract dose-dependently down-regulated the excess levels of MDA in 
monocyte cultures of postmenopausal patients. 
Secretion of cytokine IL-1P and generation of ROS, as reflected by 
suppressed GPx activity and GSH levels in postmenopausal patients, were 
mediated through activation of NFKB as evidenced by their suppression in 
monocyte cultures in the presence of SN50, an inhibitor of NFKB while 
SN50/M, an inactive analogue of SN50, failed to show any such effect. 
Furthermore, NAG, a precursor of in vivo antioxidant glutathione, caused 
suppression of IL-1|3 secretion and exhibited enhancement / amelioration of 
intramonocyte GSH levels. Interestingly, allicin and neem extract showed a 
higher degree of inhibition of cytokine secretion and enhanced antioxidant 
effect in comparison to NAG, thereby, proving these as effective natural 
herbal antagonists of pathogenesis of postmenopausal osteoporosis. 
Allicin (diallyl thiosulfinate) is the major biologically active thiosulfinate 
compound of freshly crushed garlic. It has been reported to possess potent 
antibacterial properties besides showing broad range antimicrobial and 
antifungal activities. Besides, allicin has radical scavenging properties in 
activated granulocytes and may also inhibit iNOS expression in activated 
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macrophages. Neem {Azadirachta indica) is one of the most versatile 
medicinal plants having a wide spectrum of biological activity. Active 
compounds of the plant are mostly isoprenoids such as nimbidin, gedunin and 
vilasinin. Its different plant parts such as leaf, bark and neem oil extracts have 
multiple properties some of which include anti-inflammatory, antipyretic and 
analgesic activities. Immunostimulant activity of neem bark and oil has been 
reported. Aqueous neem leaf extract is known to have significant 
hypoglycemic effect. Anti-malarial, anti-bacterial and anti-fungal properties of 
neem bark, leaf and oil extract have been detected. Furthemore, 
anticarcinogenic activity of neem leaf extract and antioxidant activity of neem 
seed extract has also been demonstrated. 
Since higher doses of Allicin have previously proven to be toxic by various 
investigators, our present study employed lower concentrations (0-500 ng/ml) 
of Allicin as well as that of neem extract (0-500 pg/ml), both of which in their 
respective range of doses, failed to show any toxic effect on human 
monocytes as revealed by MTT assay. Also no effect was observed on 
human housekeeping gene R18 as revealed by real-time RT-PCR, thereby 
Indicating that allicin and neem extract did not non-specifically affect TNF a 
and OPG transcription in patient monocytes nor cause cellular death. 
Furthermore, the present study revealed both allicin and neem extract to up-
regulate the activity of GPx in the monocyte cultures of postmenopausal 
patients in a dose-dependent manner. The results indicate an appreciable 
increase in GPx activity by -53% at 500 ng/ml allicin and -55% at 500 pg/ml 
neem extract. Enhancement of GPx activity in postmenopausal patient 
monocyte cultures indicates reversal of impaired neutralizing mechanisms. 
Similarly, allicin and neem extract were also found to appreciably up-regulate 
the intramonocyte GSH levels in these patients in a dose-dependent manner. 
Interestingly, in comparison to NAC and SN50, allicin and neem extract both 
exerted more efficient restoration of decreased antioxidant power indicating 
these compounds to be effective herbal antioxidants combating ROS, 
generated as a consequence of excess cellular activation in monocytes of 
postmenopausal patients. 
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Intracellular signaling pathways, especially NFKB, are known to be ROS 
sensitive. Our results indicate that the increased secretion of TNF-a and IL-ip 
at protein levels as well as TNF-a and OPG at the gene i. e. mRNA levels, 
and excess ROS generation as mirrored by decreased GPx activity and GSH 
levels, are interconnected and involve cellular activation of NFKB. This fact is 
evidenced by the suppression of TNF-a, OPG and IL-1P expressions at the 
protein and gene levels and up-regulation of GSH levels in the presence of 
SN50, an inhibitor of NFKB. SN50/M, an inactive analogue of SN50, failed to 
show any such effect. In view of it, our data demonstrate that this effect 
involved inhibition of NFKB pathway induced by allicin and neem extract 
probably by inhibiting the degradation of IKBO. Since a number of genes 
involved in inflammatory responses are regulated by NFKB pathway, thus a 
high magnitude down-regulation of this pathway by allicin and neem extract 
would predictably reduce the elaboration of NFKB-mediated TNF-a, OPG and 
IL-ip expressions as well as generation of ROS. 
In conclusion, the presence of high levels of proinflammatory cytokines such 
as IL-ip, TNF a and a related TNFR super family member OPG together with 
antioxidant deficiency in terms of both low GPx activity and GSH levels and a 
simultaneous increase in MDA levels add to the severity of estrogen 
deficiency bone loss. Our study shows appreciable reversal of impaired 
neutralizing mechanisms by allicin and neem extract which correlates 
inversely with the down-regulation of TNF a, IL-ip, and OPG expressions in 
monocytes of postmenopausal osteoporotic patients. Thus, allicin and neem 
extract may prove to be valuable natural antioxidant and anti-inflammatory 
agents in the management of postmenopausal osteoporosis and, therefore, 
be useful adjuncts in the treatment of estrogen deficiency bone loss. These 
observations strengthen the idea that allicin and neem extract should be 
tested in in vivo models to evaluate their therapeutic potential in the 
pathogenesis of postmenopausal osteoporosis. 
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Abstract 
Osteoporosis is as old as the origin of human civilization yet complete 
understanding about it remains to be achieved till date. Osteoporosis and 
associated fractures constitute a major public health issue together 
representing an important cause of mortality and morbidity with annual 
incidence of fracture rates exceeding the combined incidence of breast 
cancer, stroke and heart attacks in postmenopausal women (PMW). 
Emergence of osteoporosis as a global bone health concern is reflected in the 
occurrence of 1.6 million hip fractures annually worldwide and the number 
projected to go up four times by 2050. Though osteoporosis affects both men 
and women, the later are more susceptible targets of this crippling bone 
disorder. 
It is long been recognized that infection, inflammation, and autoimmune 
disorders are associated with systemic and local bone loss. Yet, it is only 
recent that T lymphocytes and their product have been recognized as key 
regulators of bone cell formation, lifespan and activity. Of many 
proinflammatory cytokines activated in postmenopausal osteoporosis, TNF-a 
is probably the dominant cytokine, which promotes osteoclastogenesis by 
augmenting the production of RANKL, the non-redundant cytokine 
responsible for osteoclast development. This ability of TNF-a is due to 
synergistic interactions at the level of NF-KB and activator protein-1 (AP-1) 
signaling. Furthermore, TNF stimulates osteoclast (OC) activity and inhibits 
osteoblastogenesis thus further driving an imbalance between bone formation 
and bone resorption. 
With ever increasing number of elderly people in the population, improved 
survival and an increase in the age-specific fracture rates, there is an 
immediate need to develop new cost-effective therapeutic strategies against 
postmenopausal osteoporosis. In view of reactive oxygen species (ROS) and 
reactive nitrogen species (RNI) playing an important role in both estrogens 
related and unrelated osteoporosis, thus, greater emphasis is now being laid 
on development of compounds from natural sources having antioxidant and 
anti-inflammatory properties in combating osteoporosis. Earlier work in our 
laboratory has proved the antioxidant and anti-inflammatory effects of allicin 
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from garlic in other diseases. Thus, we studied the incorporation of such 
compounds like allicin from garlic, and neem extract as natural herbal 
treatment for estrogen - related / unrelated deficiency bone loss. 
The initial phase of the present study undertook a detailed characterization of 
sera and monocytes of postmenopausal patients to assess the activity of 
predominant antioxidant enzyme, GPx and to measure the intramonocyte 
(GSH) levels. Glutathione (GSH) directly reacts with ROS, and glutathione 
peroxidase (GPx) catalyses the removal of hydrogen peroxide. ELISA results 
showed almost less than half the activity of enzyme both in sera and 
monocytes of postmenopausal patients as compared to premenopausal non-
porotic (Pre-M-NP) healthy individuals. Decrease in GPx activity therefore, 
indicates impairment of hydrogen peroxide-neutralizing mechanism. A similar 
suppression in intramonocyte GSH levels was observed in these patients 
indicative of weak antioxidant power. The presence of elevated free radicals 
in postmenopausal patients was also substantiated by MDA determination. 
Considerable evidence has accumulated that suggests that estrogen prevents 
bone loss by blocking the production of proinflammatory cytokines by bone 
marrow stromal and bone cells. Cytokines regulated by estrogen are IL-1, IL-6 
and TNF a. In our study also, estimation by ELISA showed an appreciable 
secretion of TNF-a and IL-ip in the sera and monocytes of postmenopausal 
patients. Infact, IL-1 is a potent stimulator of bone resorption together with 
TNF, and both are well-recognized inhibitors of bone formation. [L-1 and TNF 
are also powerful inducers of other cytokines such as IL-6, M-CSF and GM-
CSF, which potentiate the effect of IL-1 on osteoclastogenesis. 
Next, an attempt was also made to characterize monocytes from 
postmenopausal patients with respect to TNF-a and osteoprotegrin (OPG). 
Monocytes from these patients were subjected to TNF-a and OPG mRNA 
evaluation by real-time RT-PCR revealing appreciably high basal levels of 
both mRNA expressions. 
Osteoporosis represents a polygenic disorder largely modified by a variety of 
factors, which include hormones and their receptors, cytokines and growth 
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factors, BMPs, and others. While RANKL is necessary for osteoclast 
differentiation, role of OPG in the pathogenesis of osteoporosis has not been 
clear since OPG levels are not consistently altered. In humans, OPG levels 
increasing with age are understood as a homeostatic response to limit the 
bone loss that occurs with an increase in other bone resorbing factors. Thus, 
in the present study, we attempted to probe the expression level of OPG 
together with TNF a and their regulation by natural antioxidants like aliicin 
from garlic and neem extract in postmenopausal osteoporosis. 
• Real-time RT-PCR data show that aliicin down-regulated the expression of 
TNF-a and OPG mRNA in PBMC's of postmenopausal patients in a dose-
dependent manner. Concentrations of 250 and 500 ngs/ml of aliicin were 
found to suppress the appreciably high basal levels of TNF and OPG mRNA's 
by ~5 and 6 logs respectively. It is to be pointed out that previous reports 
indicated higher doses of aliicin were toxic to human cells. However, our 
laboratory has shown lower doses to be non-toxic and proved to be potent 
anti-inflammatory agent in other disease conditions such as tuberculosis. 
From our data, it is evident that whereas low concentrations of aliicin used in 
this study appreciably down-regulate the mRNA expression of TNF a and 
OPG, at the same time show no significant effect on the expression of human 
housekeeping gene R18. Thus, low dose of aliicin used in the study was non-
toxic. 
Similarly, real-time RT-PCR data show that neem extract also down-regulated 
the expression of TNF-a and OPG mRNA in PBMCs of postmenopausal 
patients in a dose-dependent manner. An appreciable suppression of TNF-a 
mRNA by ~5 and 6 logs and of OPG mRNA by ~4 and 6 logs were recorded 
at 250 and 500 pg/ml neem extract respectively. 
Thus, although OPG is produced in many tissues, bone derived OPG may be 
released into circulation, thereby reflecting the situation locally in bone. Our 
results showing increased OPG mRNA expression in the postmenopausal 
patient PBMC's therefore may indicate a compensatory response to increased 
osteoclastic bone resorption and the resultant bone loss caused by estrogen 
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deficiency; this considering the fact that OPG has bone sparing activity. The 
expression of OPG mRNA correlated positively with that of TNF a mRNA 
expression. Therefore, OPG, a soluble member of TNFR super family of 
proteins plays an important role in the negative regulation of osteoclastic bone 
resorption. 
Next, the levels of malondialdehyde (MDA), a by-product of lipid peroxidation 
were observed to be appreciably high both in sera and monocyte cultures of 
postmenopausal patients further pointing to the increased oxidant stress in 
such women. Subsequent increase in hydrogen peroxide levels due to 
depressed GSH levels and GPx activity in postmenopausal patients might 
have induced the peroxidation of polyunsaturated fatty acids, thereby leading 
to the formation of high MDA levels. Moreover, due to high reactivity of MDA 
towards amino groups may also lead to deactivation of enzymes. Allicin and 
neem extract dose-dependently down-regulated the excess levels of MDA in 
monocyte cultures of postmenopausal patients. 
Secretion of cytokine IL-ip and generation of ROS, as reflected by 
suppressed GPx activity and GSH levels in postmenopausal patients, were 
mediated through activation of NFKB as evidenced by their suppression in 
monocyte cultures in the presence of SN50, an inhibitor of NFKB while 
SN50/M, an inactive analogue of SN50, failed to show any such effect. 
Furthermore, NAC, a precursor of in vivo antioxidant glutathione, caused 
suppression of IL-1(3 secretion and exhibited enhancement / amelioration of 
intramonocyte GSH levels. Interestingly, allicin and neem extract showed a 
higher degree of inhibition of cytokine secretion and enhanced antioxidant 
effect in comparison to NAC, thereby, proving these as effective natural 
herbal antagonists of pathogenesis of postmenopausal osteoporosis. 
Allicin (diallyl thiosulfinate) is the major biologically active thiosulfinate 
compound of freshly crushed garlic. It has been reported to possess potent 
antibacterial properties besides showing broad range antimicrobial and 
antifungal activities. Besides, allicin has radical scavenging properties in 
activated granulocytes and may also inhibit iNOS expression in activated 
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macrophages. Neem {Azadirachta indica) is one of the most versatile 
medicinal plants having a wide spectrum of biological activity. Active 
compounds of the plant are mostly isoprenoids such as nimbidin, gedunin and 
vilasinin. Its different plant parts such as leaf, bark and neem oil extracts have 
multiple properties some of which include anti-inflammatory, antipyretic and 
analgesic activities. Immunostimulant activity of neem bark and oil has been 
reported. Aqueous neem leaf extract is known to have significant 
hypoglycemic effect. Anti-malarial, anti-bacterial and anti-fungal properties of 
neem bark, leaf and oil extract have been detected. Furthemore, 
anticarcinogenic activity of neem leaf extract and antioxidant activity of neem 
seed extract has also been demonstrated. 
Since higher doses of Allicin have previously proven to be toxic by various 
investigators, our present study employed lower concentrations (0-500 ng/ml) 
of Allicin as well as that of neem extract (0-500 pg/ml), both of which in their 
respective range of doses, failed to show any toxic effect on human 
monocytes as revealed by MTT assay. Also no effect was observed on 
human housekeeping gene R18 as revealed by real-time RT-PCR, thereby 
indicating that allicin and neem extract did not non-specifically affect TNF a 
and OPG transcription in patient monocytes nor cause cellular death. 
Furthermore, the present study revealed both allicin and neem extract to up-
regulate the activity of GPx in the monocyte cultures of postmenopausal 
patients in a dose-dependent manner. The results indicate an appreciable 
increase in GPx activity by ~53% at 500 ng/ml allicin and ~55% at 500 pg/ml 
neem extract. Enhancement of GPx activity in postmenopausal patient 
monocyte cultures indicates reversal of impaired neutralizing mechanisms. 
Similarly, allicin and neem extract were also found to appreciably up-regulate 
the intramonocyte GSH levels in these patients in a dose-dependent manner. 
Interestingly, in comparison to NAC and 3N50, allicin and neem extract both 
exerted more efficient restoration of decreased antioxidant power indicating 
these compounds to be effective herbal antioxidants combating ROS, 
generated as a consequence of excess cellular activation in monocytes of 
postmenopausal patients. 
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Intracellular signaling pathways, especially NFKB, are known to be ROS 
sensitive. Our results indicate that the increased secretion of TNF-a and IL-ip 
at protein levels as well as TNF-a and OPG at the gene i. e. mRNA levels, 
and excess ROS generation as mirrored by decreased GPx activity and GSH 
levels, are interconnected and involve cellular activation of NFKB. This fact is 
evidenced by the suppression of TNF-a, OPG and IL-1P expressions at the 
protein and gene levels and up-regulation of GSH levels in the presence of 
SN50, an inhibitor of NFKB. SN50/M, an inactive analogue of SN50, failed to 
show any such effect. In view of it, our data demonstrate that this effect 
involved inhibition of NFKB pathway induced by allicin and neem extract 
probably by inhibiting the degradation of IKBO. Since a number of genes 
involved in inflammatory responses are regulated by NFKB pathway, thus a 
high magnitude down-regulation of this pathway by allicin and neem extract 
would predictably reduce the elaboration of NFKB-mediated TNF-a, OPG and 
IL-1 (3 expressions as well as generation of ROS. 
In conclusion, the presence of high levels of proinflammatory cytokines such 
as IL-ip, TNF a and a related TNFR super family member OPG together with 
antioxidant deficiency in terms of both low GPx activity and GSH levels and a 
simultaneous increase in MDA levels add to the severity of estrogen 
deficiency bone loss. Our study shows appreciable reversal of impaired 
neutralizing mechanisms by allicin and neem extract which correlates 
inversely with the down-regulation of TNF a, IL-ip, and OPG expressions in 
monocytes of postmenopausal osteoporotic patients. Thus, allicin and neem 
extract may prove to be valuable natural antioxidant and anti-inflammatory 
agents in the management of postmenopausal osteoporosis and, therefore, 
be useful adjuncts in the treatment of estrogen deficiency bone loss. These 
observations strengthen the idea that allicin and neem extract should be 
tested in in vivo models to evaluate their therapeutic potential in the 
pathogenesis of postmenopausal osteoporosis. 
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Introduction 
Osteoporosis is a heterogeneous metabolic disorder characterized by a 
progressive loss of bone tissue in the increasingly ageing population 
responsible for the increase in bone fragility with a tendency to fracture 
following minimal trauma. 
Epidemiology 
Osteoporosis and associated fractures constitute a major public health 
concern, together representing an important cause of mortality and morbidity 
with annual incidence of fracture rates exceeding the combined incidence of 
breast cancer, stroke and heart attacks in postmenopausal women. According 
to World Health Organization (WHO), osteoporosis is secondary only to 
cardiovascular disease as a global health care problem. Medical studies show 
a fifty-year-old woman has a similar lifetime risk of dying from hip fracture as 
from breast cancer. Osteoporosis currently affects up to 1 in 3 women and 1 
in 12 men at some point in their lives (Keen, 2003). As per reports, 
approximately 1.6 million hip fractures occur worldwide every year, the 
incidence is set to increase to 6.3 million by 2050 (Cooper et al., 1992). This 
increase in the number of fractures is due to an increase in the number of 
elderly people in the population, improved survival, and an increase in the age 
specific fracture rates. 
An estimated 10 million Americans have osteoporosis, while another 34 
million have low bone mass and are at risk of developing osteoporosis, 80% 
of these being women. The direct care cost for osteoporotic fractures in USA 
alone are up to $18billJon each year. In UK the incidence is set to increase in 
line with the ageing British population, as fracture risk increases exponentially 
with age and the current annual £1 billion cost will increase accordingly 
(Putnam et a!., 2007). With socio-economic development in many Asian 
countries and rapid ageing of the Asian population, osteoporosis has become 
one of the most prevalent and costly health affair in the region; by 2050, 1 out 
of every 2 hip fractures worldwide will occur in Asia (Riggs and Melton., 
1995). in India, 1 out of 8 males and 1 out of 3 females suffer from 
osteoporosis, making India one of the largest affected countries in the world. 
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The number of osteoporotic patients is pegged at approxinnately 26 million 
(2003 figures) with the numbers projected to increase to 36 million by 2013. In 
China, osteoporosis has reached epidemic proportion, 300% increase in the 
last 30 years. Osteoporosis is currently among the top five conditions causing 
disability and prolonged hospital stay for elderly in Hong Kong. The mortality 
rate for hip fracture patients in Hong Kong is 20% while 70% remain 
permanently disabled and the total cost of the disease is projected to reach 
$128 million by the year 2010. In Singapore, more than 100,000 women suffer 
from osteoporosis, with fracture treatment adding upto $3.4million a year. The 
total number of osteoporotic patients in Japan is estimated to be 10 million 
(2004 figures). In Australia, 2 million people are affected and the burden of 
disease equaling to $7.4 billion per year. Korea is estimated with as many as 
2 million people suffering from osteoporosis, the prevalence of hip fractures 
increased about 4-folds during the past decade. The current global magnitude 
of osteoporotic fractures therefore, presses for the immediate need to develop 
new cost-effective therapeutic agents to check the enormous cost in terms of 
both physical disability and economic losses (Ricjgs and Melton., 1995; Melton 
etal., 1997; Wark, 1996). 
Current Treatment of Osteoporosis and its Disadvantages. 
Pharmacological treatments available for osteoporosis are divided into two 
broad categories; (1) anti-resorptive, which include bisphosphonates, 
hormone replacement therapy (HRT), selective estrogen receptor modulators 
(SERMs), calcitonin (CT), vitamin D analogues and combination therapy of 
calcium and vitamin D, and (2) anabolic, which include sodium fluoride, 
anabolic steroids and parathyroid hormone (PTH) as well as related peptide. 
Although currently in use, all have serious disadvantages, e.g., the 
bisphosphonates, the most widely used drugs for the treatment of established 
osteoporosis, act by binding to hydroxyapatite and inhibiting osteoclasts at 
their resorption sites. Side effects include nausea, vomiting, diarrhea, peptic 
ulceration, abdominal pain and constipation along with allergic skin reactions 
and the possibility of osteomalacia (Ferguson, 2004). HRT confers an 
increased risk of pulmonary embolism and breast cancer, and has many 
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contraindications (Ferguson, 2004). There is insufficient evidence of benefits, 
but reliable evidence of harm (Bruyere et a!., 2003) is more prominent 
Selective estrogen receptor modulator (SERM), for example, raloxifene, acts 
in a similar manner to HRT but with less of a risk of breast cancer, however, 
still carries the risk of venous thromboembolism (Ferguson, 2004). Calcitonin, 
a polypeptide hormone produced by the thyroid gland, acts to decrease bone 
resorption by inhibiting the activity of osteoclasts through binding to calcitonin 
receptors on the osteoclast. Side effects include flushing, nausea, vomiting, 
and diarrhea. Calcitriol (1,25-dihydroxy vitamin D3) increases intestinal 
absorption of calcium and promotes mineralization of bone. Its efficacy is 
mainly proven in milder cases of osteoporosis whilst side effects include 
hypercalcaemia and hypercalciuria. 
Anabolic agents increase the number and activity of osteoblasts, but also of 
osteoclasts, resulting in a net increase of bone at cortical sites. Side effects of 
the drug are male characteristics in women, and liver toxicity (Ferguson, 
2004). PTH acts primarily to sustain or increase plasma calcium levels. PTH 
has anabolic effects on bone, which result from binding to receptors on 
osteoblast surface, thus promoting osteoblast cell proliferation via a signaling 
pathway involving two second messengers (Berne & Levy, 1998). PTH and 
PTH-related protein (PTHrP), low doses of both, are the most promising 
anabolic treatment for osteoporosis thus far, however, high levels can cause 
increased bone resorption and osteitis fibrosa cystica (Manologas, 2000). 
Future studies to assess the anti-fracture efficacy of these compounds will be 
needed before their effectiveness for the management of osteoporosis can be 
established. 
Clinical Manifestations and Risk Factors 
Osteoporosis is often called the "silent disease" because bone loss occurs 
without symptoms. Fracture is the only clinical manifestation of osteoporosis 
and occurs at a relatively late stage in the disease when bone loss may 
already be advanced. Three main types of osteoporotic fractures are wrist, 
vertebral and hip fracture. Collapsed vertebra may initially be felt or seen in 
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the form of severe back pain, loss of height or spinal deformities such as 
kyphosis or severely stooped posture. 
Of risk factors, age is the greatest associated with osteoporosis as it 
decreases levels of PTH and CT, which in turn increase the level of bone 
resorption. Osteoblast function and calcium absorption also decrease with 
age (Tanna, 2005). There are other factors that govern the likelihood of 
developing osteoporosis; some of which are modifiable, e.g., lifestyle, diet and 
estrogen deficiency, and others non-modifiable, such as genetics and certain 
drug therapies (Ferguson, 2004). The main lifestyle risk factors include a lack 
of load bearing exercise, excessive alcohol intake and cigarette smoking, a 
lifetime diet low in calcium and vitamin D, premature or surgical menopause 
(Tanna,2005). Non modifiable genetic factors which predispose a person to 
osteoporosis include a small body frame, a family history of osteoporosis, 
race (Caucasians and Asians being at increased risk), skin type and also 
being woman is a risk. Long-term drug therapy with corticosteroids, heparin, 
cyclosporine, cytotoxics or certain anticonvulsants can also put a person at 
risk (Ferguson, 2004). 
Bone Pathophysiology 
Bone is a complex tissue composed of cells, collagenous matrix, and 
inorganic elements. It provides many essential functions, including 
mechanical support, protection of vital organs, a microenvironment for 
hematopoiesis, and a depot for calcium and other minerals. The growth, 
development, and maintenance of bone is a highly regulated process 
(Nijweide et al, 1986). The level of bone mass reflects the balance of bone 
formation and resorption, which at the cellular level involves the synthesis of 
bone matrix by osteoblasts and the coordinate resorption of bone by 
osteoclasts (Felix et al, 1996; Roodman,1996). Osteoblasts and osteoclasts 
arise from distinct cell lineages and maturation processes; osteoblasts arise 
from mesenchymal stem cells, whereas osteoclasts differentiate from 
hematopoietic monocytes/macrophage precursors. Both cell types are 
influenced by a wide variety of hormones, inflammatory mediators, and growth 
Introduction 
factors (Suda et al, 1992; Mundy, 1993a, 1993b). An imbalance of osteoblast 
and/or osteoclast functions can result in skeletal abnormalities characterized 
by increased (osteopetrosis) or decreased (osteoporosis) bone mass. 
Low bone mass results due to inadequate peak bone mass during grov\rth, 
excessive bone resorption and inadequate formation of new bone during 
remodeling. Hormonal factors strongly determine the rate of bone resorption, 
lack of estrogen increases bone resorption as well as decreasing the 
deposition of new bone that normally takes place in weight bearing bones. 
Besides estrogen, calcium metabolism plays a significant role in bone 
turnover. Deficiency of calcium and vitamin D leads to impaired bone 
deposition. Moreover, the parathyroid glands react to low calcium levels by 
secreting PTH, which increases bone resorption to ensure sufficient calcium 
in the blood. The role of CT, a hormone generated by the thyroid that 
increases bone deposition, is less clear and probably less significant (Raisz, 
2005). Several forms of osteoporosis have been identified. Osteoporosis can 
be therefore, classified as primary which includes postmenopausal (Type I) or 
secondary which includes senile (Type II) osteoporosis. The Type I variety 
occurs typically between 55-75 years, affects mainly trabecular bone and is 
more common in women than in men (6:1 ratic). Prior to menopause, bone 
loss occurs at the rate of 0.5-1% per year. At menopause, bone loss 
accelerates at the rate of 2-5% per year due to decline in estrogen levels and 
is greatest in the first 3-6 years post menopause. The Type II or age-related 
osteoporosis occurs after the age of 70 years, affects both cortical and 
trabecular bone inflicting women twice as frequently as men. Secondary 
osteoporosis can occur due to specific causes such as an endocrine disease 
(e.g., hyperparathyroidism, hyperthyroidism, glucocorticoid excess, 
hypogonadism, etc.), drug induced (e.g., glucocorticosteroids, barbiturates, 
heparin, alcohol, etc.), congenital conditions (e.g., homocystinuria, hemolytic 
anemia, hypophosphatasia, osteogenesis imperfecta), diet conditions (e.g., 
anorexia nervosa, calcium deficiency, malabsorption syndromes, etc.) and 
miscellaneous conditions (e.g., prolonged immobilization, rheumatoid arthritis, 
chronic liver failure, diabetes mellitus, etc.). 
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DIAGNOSIS 
The last decade has seen new diagnostic and therapeutic options for the 
management of postmenopausal osteoporosis. The diagnostic process should 
focus on determining the type and degree of bone loss. The important 
methods that are widely used globally for the diagnosis of osteoporosis are 
given below: 
(a) Measurement of Bone Mineral Density (BMD) 
BMD testing is the preferred method to diagnose osteoporosis. The newer 
diagnostic modalities are dual energy X- ray absorptiometry (DXA), single 
energy X- ray absorptiometry (SXA), quantitative ultrasonography (QUS), 
quantitative computerized tomography (QCT), single photon absorptiometry 
(SPA), double-photon-absorptiometry (DPA). BMD is a continuous measure of 
fracture risk, just as serum lipid levels and blood pressure are continuous 
measures of certain cardiovascular risks. For each SD reduction in bone 
mass, there is a two-fold rise in fracture risk (Marshall et al, 1996). 
(b) Bone Turnover Markers 
Biochemical markers of bone turnover reflect bone formation or bone 
resorption. Osteocalcin and bone-specific alkaline phosphatase (BSAP) are 
the most commonly used serum markers of bone formation. Of note, 
osteocalcin also reflects bone resorption, because it is released into 
circulation from the matrix during this process. BSAP is produced by OBs and 
is an enzyme necessary for bone mineralisation. Other markers of bone 
formation are carboxy- and amino-terminal propeptide of type 1 collagen; 
however, the presence of type 1 collagen in other tissues makes these 
markers less clinically helpful. Urinary levels of N- and C-telopeptide of 
collagen cross-links (NTX and CTX), free and total pyridinolines (Pyd), 
deoxypyridinolines (Dpd), and hydroxyproline are used as markers of bone 
resorption. Several studies have shown that high bone turnover is associated 
with lower bone mass, more rapid bone loss, and an Increased propensity for 
fracture and vice-versa. However, the variation is too large for diagnostic use 
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in individual patients (Delmas, 1993; Hansen et al, 1991; Riis, 1995). 
Biochemical markers of bone turnover cannot diagnose osteoporosis, predict 
bone density, or predict fracture risk; however these tests are of immense use 
in predicting the therapeutic response. Bone turnover changes can provide 
evidence of osteoporosis therapy efficacy much earlier than BMD changes. 
REVIEW OF LITERATURE: 
1. Bone Remodeling - Physiology and Pathophysiology 
Skeletal integrity is the result of dynamic interaction between bone forming 
osteoblasts (OBs) and bone resorbing osteoclasts (OCs). During embryonic 
development and post-natal growth, the amount of bone formed exceeds that 
being resorbed. In the adult skeleton, which is continuously remodeled, the 
two processes are tightly coupled and in balance, resulting in the preservation 
of bone mass achieved during growth. The physiological remodeling of bone 
takes place in so called "bone multi-cellular units" (BMUs) and is initiated by 
recruitment, formation, and activation of bone-resorbing OCs. These cells 
adhere to bone and subsequently resorb a given volume of bone by 
acidification and proteolytic digestion. Shortly after the OCs have left the 
resorption site, OBs invade the area and begin the process of forming new 
bone by secreting osteoid (a matrix of collagen and other proteins), which is 
eventually mineralized. After bone formation has ceased, lining cells cover the 
surface of the bone, which is a distinct type of terminally differentiated 
osteoblasts (Parfitt, 1994). Such BMUs are present both at the surfaces of 
trabecular and cortical bone and in the Harversian canals of cortical bone but 
are more frequent in trabecular bone. This is the reason, osteoporosis - a 
metabolic bone disease, primarily affects bones with a large proportion of 
trabecular bone. In pathological situations, bone formation and bone 
resorption are often uncoupled, resulting in either loss of bone (osteoporosis, 
rheumatoid arthritis, periodontal bone disease and most malignant tumors) or 
gain of bone (osteopetrosis, certain malignant tumors and some inflammatory 
conditions / bone pathologies). The differentiation or lifespan of OB and OC is 
believed to be particularly important in pathogenesis of these bone diseases 
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(Taitelbaum.,2000; Zaidi et al.,2003; Romas et al.,2002). OC formation from 
hematopoietic precursors requires factors that promote their differentiation 
and survival. Such factors are produced by stromal / osteoblastic cells that 
originate from mesenchymal progenitors residing in the bone marrow. Two 
such factors appear to be essential. One is macrophage colony stimulating 
factor (M-CSF), which is necessary but not sufficient for OC formation. The 
other is a membrane cytokine, receptor activator of nuclear factor kappa B 
(NF-KB) ligand (RANKL). RANKL is essential and together with M-CSF, is 
sufficient for OC differentiation. RANKL acts by binding to its receptor, RANK, 
on the surface of hematopoietic precursors, stimulating their differentiation 
into mature OCs. The action of RANKL is prevented by osteoprotegerin 
(OPG), a soluble decoy receptor that competes with RANK for binding to 
RANKL and also is expressed by OBs (Boyle et al., 2003, Walsh et al., 2003). 
2. The TNF Family Molecules in Physiological and Pathological Bone 
Resorption 
(a) Receptor activator of nuclear factor kappa B ligand (RANKL) 
Human RANKL [(also called tumor necrosis factor super family 2 (TNFSFII) / 
TNF-related activation-induced cytokine (TRANCE) / osteoprotegerin ligand 
(OPGL) /osteoclast differentiation factor (ODF)], a cytokine independently 
discovered by four different groups (Wong et al., 1997; Anderson et al., 1997; 
Yasuda et al., 1998; Lacey et al., 1998), is a member of the TNF ligand super 
family that also includes TNF- a, CD40 ligand. Fas ligand, CD30 ligand, 
TWEAK, and TRAIL (Locksley et al., 2001). RANKL is a type II membrane-
embedded protein, with a large extracellular receptor-binding domain, a 
membrane-anchoring domain, and a connecting stalk. The RANKL gene is 
present on human chromosome 13q14 and on mouse chromosome 14. The 
mouse and human RANKL consists of 316 and 317 amino acid (aa) residues, 
respectively. The homology within the TNF ligand family is confined to 
domains involved in monomer folding and trimer assembly. The shape of the 
ligand is that of an inverted bell, which at the base interacts with the receptors 
in 3:3 symmetric complex. The trimeric protein contains four unique surface 
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loops that create the specificity in its interaction with the receptor RANK 
(Lerner., 2004). Like several other TNF-like type II proteins, RANKL trimers 
exist either as membrane-anchored proteins or in a soluble cleaved form, both 
being functionally active (Nakashima et al., 2000). RANKL mRNA is 
expressed at the highest levels in bone and bone marrow and in lymphoid 
tissues (lymph node, thymus, spleen fetal liver, and Payer's patches) (Wong 
et al., 1997; Anderson et al., 1997; Yasuda et al., 1998; Lacey et al., 1998). Its 
major role in bone is the stimulation of OC differentiation (Lacey et al., 1998; 
Malyankar et al.,2000) and inhibition of OC apoptosis (Fuller et al., 1998). In 
addition, RANKL has a number of effects on immune cells, including 
activation of c-Jun N-terminal kinase (JNK) in T cells (Wong et al., 1997), 
inhibition of apoptosis of dendritic cells (Wong et al., 1997), and alterations in 
cytokine-activated T cell proliferation (Anderson et al,, 1997). RANKL 
knockout mice have severe osteopetrosis (Kong et al., 1999) and complete 
absence of OCs. In addition, they exhibit defects in early differentiation of T 
and B cells, lack lymph nodes, and have defects in thymic differentiation and 
mammary gland development (Kong et al., 1999; Fata et al., 2000). The 
promoter region of the RANKL gene contains a response element for core-
binding factor a l (Cbfa-1 or Runx2) which is a transcription factor crucial for 
OB differentiation and expression of bone matrix proteins (Ducey et. al., 
1997). 
(b) Receptor activator of nuclear factor kappa B (RANK) 
RANK, a member of the TNF receptor superfamily, is a type I transmembrane 
protein containing four cysteine-rich pseudorepeat domains in the 
extracellular region, a hallmark of the TNF-R family (Locksley et al., 2001). 
The mouse and human RANK contain 625 and 616 aa residues, respectively, 
the latter having a signal peptide (28 aa ), an N-terminal extracellular domain 
(184 aa ), a transmembrane spanning domain (21 aa), and a large C-terminal 
cytoplasmic tail (383 aa). In the human genome, RANK is present on 
chromosome 18q22.1. The extracellular part of TNF-R-like receptors forms 
elongated structures by a scaffold of disulfide bridges, which fit into the 
inverted bell / groove of the ligand trimer in a 3:3 complex (Locksley et al.. 
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2001). This has recently been demonstrated to be true for the interaction 
between RANKL and RANK (Lam et a!., 2001). Although RANK is 
ubiquitously expressed in human tissues, its cell surface expression is limited 
to dendritic cells, the CD4+ T cell line MP-1, foreskin fibroblasts, OC 
precursors, and certain Hodgkin lymphomas (Anderson et al., 1997; Hsu et 
al., 1999; Fiumara et al., 2001). RANK knockout mice lack peripheral lymph 
nodes and have defective T and B cell maturation (Li, J et al., 2000). 
(c) Osteoprotegerin (OPG) 
Osteoprotegerin (OPG) was initially discovered as an 'osteoclast inhibitory 
factor' (OCIF) or TNF receptor-like molecule (TR-1) released as a heparin-
binding protein from human skin fibroblasts and found to inhibit OC formation 
in vitro (Tsuda et al., 1997). OPG is synthesized in humans, rats, and mice as 
a 401-aa protein, which, after cleavage of 21-aa signal peptide, results in a 
380-aa mature protein. In humans, the OPG gene is located on chromosome 
8q23-24. The aa sequence of OPG displays several homologies to members 
of the TNF-R superfamily, including RANK. The 60-kDa-monomer OPG 
protein forms 120-kDa disulfide-linked homodimers containing several N-
glycosylation sites. OPG contains four cysteine-rich domains in the N-terminal 
end, two homologous 'death domains' (DDH) in the C-terminus, a heparin-
binding site, and a cysteine residue required for homodimerisation but, in 
contrast to other members of the TNF-R superfamily, lacks a transmembrane 
spanning domain and a cytoplasmic tail. Secreted OPG acts as a 'decoy 
receptor' due to its affinity to both membrane-bound and soluble RANKL and 
prevents the activation of RANK. OPG mRNA has been detected in bone, 
cartilage, aorta, skin, lung, heart, kidney, liver, brain, and in several other 
tissues. At the cellular level, OPG is expressed in OBs, stromal cells, 
endothelial cells, aortic smooth-muscle cells, fibroblasts, dendritic cells, and 
lymphoid cell lines (Lerner. 2004). 
There is in vivo evidence available that OPG-knockout mice exhibit severe 
osteopenia (Mizuno et al., 1998) and that recombinant OPG increases bone 
density and protects against bone loss due to estrogen deficiency in rat 
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(Simonet et al., 1997). In humans, however, serum OPG has been shown to 
be higher in post-menopausal women with osteoporosis (Yano et a!., 1999) 
whereby it has been thought to be compensatory mechanism to the increased 
bone turnover as a result of estrogen deficiency. In other studies also, the 
circulating OPG levels have been shown to decrease gradually following 
treatment of human PBMC's with either estrogen or raloxifene (Bashir et a!., 
2005). Contrasting results whereby estrogen stimulates gene expression of 
OPG in human osteoblastic cells (Hofbauer et al., 1999) and in mouse stromal 
cell line, ST-2 (Saiko et al., 2001) may in part, reflect differences owning to 
the different cell cultures employed. 
3. Signaling Pathways in Osteoclastogenesis 
Recognition and binding of the RANK by RANKL is the key osteoclastogenic 
event, inducing a number of parallel signaling cascades. Three important 
pathways in osteoclastogenesis are known which are described below. 
(a) NF-KB activation pathway. 
(b) NFAT/AP-1,and 
(c) The calcineurin / NFAT signaling pathway. 
(a) NF-KB activation pathway. 
RANK activation by RANKL is followed by its interaction with TNF receptor-
associated factors (TRAF) family members TRAF2, TRAF3, TRAF5, and 
TRAF6 (Wong et al., 1998; Darnay et al., 1998; Darnay et al., 1999; Darnay et 
al., 1999), which in turn recruits NF-KB inducing kinase leading to the 
activation of NF-KB (Darnay et al., 1999). TRAF6 and NF-KB play an 
indispensable role in OC differentiation as demonstrated by the osteopetrotic 
phenotype of TRAF6 and NF-KB knockouts (Lomaga et al., 1999; Lotsova et 
al., 1997). NF-KB is a dimer consisting of the NF-KB / Rel family proteins 
which include p50, p52, p65, c-Rel, and Rel-B. In unstimulated cells, NF-KB 
dimer in cytosol is present as an inactive form complexed with an inhibitory 
protein IKB, two major forms of which are IKB-Q (Haskill et al., 1991) and IKB-
P (Thompson et al., 1995). When stimulated by stimulatory cytokine, such as 
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TNF- a, the NF-KB dimer dissociates from IKB and translocates to tfie nucleus, 
the process being called 'activation of NF-KB'. The activated NF-KB dimer 
binds to the regulatory NF-KB elements in the target genes and regulates their 
transcription (Baeuerle and Hankel, 1994). 
(b) NFAT/AP-1 
In 2002, Takayanagi et al identified NFAr2 by genome-wide screening as the 
predominant gene activated in osteoclast precursors under the influence of 
RANKL. RANKL facilitates its nuclear translocation where NFAT binds to its 
DNA response element via a ternary complex with AP-1 proteins, including 
Fos / Jun, to transactivate target genes (Macian et al., 2001). NFAT/Fos/Jun 
is a critical osteoclastogenic complex, and deletion of any one of the three 
arrests OC formation (Ikeda et al., 2004). 
(c) The Calcineurin /NFAT signaling pathway 
Calcineurin is best known for its role during T-cell activation, where it acts to 
regulate the activity of the nuclear factor of activated T cells (NFAT) family of 
transcription factors and thereby couples stimulation of the T cell antigen-
receptor to changes in the expression of cytokines and other important 
immunoregulatory genes (Rao et al., 1997; Crabtree et al., 2002). 
RANK stimulation can activate calcium dependent signaling events via the 
effects of the Src tyrosine kinase on phospholipase C (Kim et al., 2002). The 
Src tyrosine kinase is coupled to RANK via its interaction with the cytoplasmic 
adaptor protein, TRAF-6 (Lomaga et al., 1999). RANK-induced activation of 
Src is likely to affect the activity of the calcineurin / NFATcl signaling pathway 
in two distinct ways. First, the TRAF-6 / Src-dependent activation of 
phospholipase C and the subsequent production of the calcium mobilizing 
agent inositol triphosphate lead to an increase in the intracellular calcium 
concentration which in turn presumably activates calcineurin, thereby inducing 
dephosphorylation of NFATd and its rapid transport into the nucleus. 
Second, the TRAF-6 / Src-dependent activation of protein kinase B likely 
results in the phosphorylation and subsequent inhibition of the principal 
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NFATd inhibitory kinase, glycogen synthase l<inase-3, thereby preventing 
this kinase from directly phosphorylating active NFATd (Beals et a!., 1997; 
Neal and Clipstone, 2001). 
Enforced expression of an activated NFATd allele in RAW264.7 cells is 
sufficient to mimic the effects of the RANKL stimulation and induce these cells 
to acquire a morphologically distinct, TRAP-positive, multinucleated 
osteoclast-like bone resorbing phenotype (Hirotani et al., 2004). It's 
noteworthy to point out that caNFATd is also able to induce the expression of 
a panel of genes including TRAP, cathepsin K, the calcitonin receptor, and 
integrin subunits, which together are considered to be molecular markers of 
fully differentiated OCs (Suda et al.,1995; Lee et al.,1995; Quinn et al.,1999; 
Tongetal., 1994) 
4. Modulation of Bone Cell Activities by TNF- a 
TNF-a is a major contributor to bone pathophysiology through stimulation of 
bone resorption and inhibition of bone formation (Nanes MS, 2003). Elevated 
levels of TNF occur after menopause, a time associated with accelerated 
bone loss (Horowitz et al., 2001; Pacifici R., 1999). TNF inhibits expression of 
genes by mature OBs, including matrix proteins, IGF-1, and receptors for PTH 
and vitamin D, while simultaneously stimulating expression of OB genes that 
are osteoclastogenic signals such as CSF-1, IL-6, RANKL and its receptor 
RANK (Nanes MS., 2003; Tanaka S et al., 2003). Besides, compromising 
function of mature OB, TNF inhibits recruitment of new OB from their 
pluripotent precursors (Abbas et al., 2003; Gilbert et al., 2000; Gilbert et al., 
2002). Low dose TNF treatment throughout a 14-day culture, or brief 
treatment during a critical period of phenotype selection, irreversibly prevents 
the appearance of OB in primary cultures of fetal rat calvaria or clonal murine 
MC3T3 preosteoblasts (Gilbert et al., 2000). This inhibitory effect is 
associated with suppression of transcription of the nuclear proteins, Runx2 
and osterlx, which are required for 0 8 differentiation and the formation of a 
mineralized skeleton (Komori T., 2003; Lian et al., 2004; Nakashima and de 
Crombrugghe. 2003). 
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TNF action begins witli binding of tine trimerised TNF protein to one of two 
cell-surface receptors, p55 (TNFR1) or p75 (TNFR2), which are responsible 
for signal transduction (Chen and Goeddel, 2002). Both forms are widely 
expressed in tissues, including bone (Kon et al, 2001) and both share signal 
pathways that activate nuclear entry of the transcription factor NFKB and 
stimulation of mitogen activated protein kinases (MAPK). However, the 
conserved TNF receptor family death domain is limited to p55 (TNFR1). 
TNF-a alone or in combination with IL-1 contributes to the increased numbers 
of OCs seen at sites of bone resorption (Konig et al., 1988). Its been recently 
shown that colony stimulating factors such as IL-3 and granulocyte 
macrophage colony stimulating factor (GM-CSF) inhibit RANKL-induced OC 
differentiation by direct action on OC precursors (Khapli et al., 2003; 
Miyamoto et al., 2001). Both colony stimulating factors completely inhibit TNF-
a-induced OC formation via action on TNFRs. TNFR1 and TNFR2 
differentially impact osteoclastogenesis. It has been reported that TNF-a 
stimulates OC formation in TNFR2-/- but fails to stimulate osteoclastogenesis 
in TNFR1-/- mice (Abu-Amer et al., 2000; Roggia et al., 2001). IL-3 and GM-
CSF have been shown to inhibit OC differentiation by downregulation of 
mRNA and surface expression of both TNFR1 and TNFR2 in OC precursors 
as well as whole bone marrow cells suggesting that IL-3 and GM-CSF down-
regulate expression of TNFR1 and TNFR2 at transcriptional and translational 
levels in the presence or absence of neighboring cells (Yogesha et al., 2005). 
TNF- a exerts pleiotropic effects on OBs or osteoblast-like cells such as 
inhibition of DMA and collagen synthesis (Nanes et al., 1989), osteocalcin 
gene expression (Nanes et al., 1991; Kuno et a!., 1994) and stimulation of 
synthesis of proteolytic enzymes such as plasminogen activators and matrix 
metalloproteinases (Panagakos and Kumar., 1994) and cytokines such as IL-
8 (Chaudhary et al., 1992). TNF-a increases mRNA levels of IL-6 and ICAM-1 
genes in the rat osteoblast-like osteosarcoma cells (ROS 17/2.8 cells) while 
an antioxidant, N-acetyl cysteine (NAC) inhibits the p50-p65 heterodimer 
activation of NFKB indicating that generation of reactive oxygen species 
(ROS) mediates the TNF-a -dependent activation of NFKB in ROS 17/2.8 
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cells. Simultaneously, NAC attenuated the TNF-a -dependent increase in the 
mRNA levels for both IL-6 and ICAM-1 (Kurocouchi et al., 1998). IL-6 
stimulates both proliferation and differentiation of the OC precursor cells 
(Roodman, 1993) and also promotes the B cell proliferation and 
differentiation, and activates T cells (Hirano et al., 1986; Houssiau and Van, 
1992). 
5. Modulation of Bone Cell Activities by Estrogen 
A network of estrogen-regulated cytokines is rasponsible for the changes in 
bone turnover and the loss of bone induced by estrogen deficiency. 
Considerable evidence has accumulated suggesting that estrogen prevents 
bone loss by blocking the production of proinflammatory cytokines by bone 
marrow and bone cells (Pacifici, 1996; Manolagas and Jilka, 1995)). The main 
consequence of increased cytokine production in the bone microenvironment 
is an increased OC formation and elongation of their life span (Roodman, 
1996). In addition, enhanced cytokine production results in increased activity 
of mature OCs and an increased osteoblastic activity, which compensates 
only in part the increased rate of bone loss. 
(a) Cytokine profile in estrogen deficiency bone loss 
Among the cytokines regulated by estrogen are IL-1, IL-6, and TNF (Pacifici, 
1996; Manolagas and Jilka, 1995). IL-1 and TNF are the most powerful locally 
produced stimulators of bone resorption and are well-recognized inhibitors of 
bone formation. IL-1 and TNF activate mature OCs indirectly via a primary 
effect on OBs and inhibit OC apoptosis. Besides, they markedly enhance OC 
formation by stimulating the proliferation of OC precursors both directly and by 
enhancing the pro-osteoclastogenic activity of stromal cells. IL-1 and TNF are 
also powerful inducers of other cytokines that regulate the differentiation of 
OC precursor cells into mature OCs such as IL-6, M-CSF and GM-CSF. IL-6 
is a potent osteoclastogenic factor that exerts its effects via a cell surface 
receptor that consists of a ligand binding chain (IL-6R) and a signal 
transducing chain known as gp130. When bound to soluble IL-6R, IL-6 
stimulates the early stages of osteoclastogenesis in human and murine 
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cultures, presumably by forming a complex with gp130 expressed on either 
stromal cell or OBs (Udagawa et al., 1995). 
IL-7 is an osteoclastogenic cytokine, the principal sources of which are the 
bone marrow, stromal cells (Fry and Mackall, 2002) and OBs (Weitzmann et 
al., 2000). IL-7 promotes osteoclastogenesis by up regulating key T cell-
derived osteoclastogenic cytokines, including RANKL (Weitzmann et al., 
2000). IL-7 also increases the number of early precursors of the B cell lineage 
(B220+ cells) in the bone marrow (Miyaura et al., 1997), a population capable 
of differentiating into OCs (Sato et al., 2001). Up regulation of IL-7 which is a 
consequence of estrogen deficiency has been shown to play a central role in 
ovx-induced bone loss by uncoupling bone formation from bone resorption 
(Weitzmann et al., 2002) whereby IL-7 treatment of osteoblastic cells led to a 
decrease in the promoter activity of Cbfa1/Runx2. Cbfa/Runx2 is both a 
marker of and a key participant in the process of OB differentiation. IL-7 
stimulates osteoclastogenesis further through downregulation of OPG, the 
decoy receptor of RANKL, due to reduction of Cbfa1/Runx2 levels. Therefore, 
IL-7 is a relevant causal agent of bone loss induced by E2 withdrawal, as the 
stimulatory effect of IL-7 on bone resorption is compounded by the inhibition 
of bone formation (Weitzmann et al., 2002). 
IL-12 is a heterodimeric cytokine that plays a central role in promoting type 1 
T helper cell (Thi) responses and, hence, cell-mediated immunity. IL-12 
induces cytokine production, primarily of IFN-y, from NK and T cells, acts as a 
growth factor for activated NK and T cells. The expression of IL-12 as well as 
IL-18 genes in bone marrow monocytes is induced by NFKB and AP-1, 
nuclear proteins whose transcriptional activity is directly repressed by 
estrogen (An J et al., 1999; Shevde et al., 2000; Galien et al., 1997). 
Unstimulated bone marrow monocytes, such as those from estrogen-replete 
mice, are known to express low or undetectable levels of NFKB and AP-1 
(Muegge et a!., 1990). Accordingly, bone marrow monocytes from such mice 
express minimal levels of IL-12 and IL-18, while those from ovx animals 
produce increased amounts of IL-12 and IL-18. Thus, one mechanism by 
which estrogen represses CIITA is by decreasing IFN-y production via an 
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inhibitory effect on the bone marrow monocyte production of IL-12 and IL-18. 
Another mechanism by which estrogen deficiency up-regulates the production 
of IFN-Y is through TGF-p. Estrogen has a direct stimulatory effect on the 
production of this factor mediated through direct binding of estrogen / 
estrogen receptor complex to an estrogen-responsive element in the TGF-p 
promoter (Yang et al., 1996). 
(b) Regulation of bone metabolism by TGF- /3 and IFN- y 
TNF-a, which is estrogen-regulated cytokine, promotes osteoclastogenesis by 
augmenting the production of RANKL (Pfeilschifter et al., 2002), the non-
redundant cytokine responsible for OC development (Hofbauer et al., 2000) 
and by increasing the responsiveness of maturing OCs to this factor (Cenci et 
al., 2000; Lam et al., 2000; Zhang et al., 2001). Ovx increases TNF levels in 
the bone marrow (BM) via an expansion of the pool of TNF-producing T cells 
(Cenci et al., 2000; Roggia et al., 2001) induced by a complex mechanism 
driven by interferon gamma (IFN-y) (Cenci et al., 2003). IFN-y augments 
antigen (Ag) presentation by enhancing MHC II expression on BM 
macrophages (BMMs), through induction of class II transactivator (CIITA) 
expression (Boss and Jensen., 2003). Up-regulation of Ag presentation 
results, in turn, in the increased T cell activation. T cell-produced TNF plays a 
key role in the ovx-induced bone loss, as demonstrated by the failure of ovx to 
induce bone loss in T cell-deficient nude mice and by the ability to reconstitute 
with WT T cells, but not TNF-/- T cells, to restore a normal response to ovx 
(Cenci et al., 2000; Roggia et al., 2001). 
TGF-P has been reported to repress the production of IFN-y by directly 
targeting T-cells and inhibiting their proliferation (Kehrl et al., 1986) and 
differentiation into effector cells (Gorelik and Flavell, 2002). Also, TGF-p is 
recognized for its ability to repress the production of and responsiveness to 
numerous cytokines relevant for bone homeostasis. For example, TGF-p 
signaling in BMMs decreases the responsiveness of the CIITA gene to IFN-y 
(Lee et al., 1997; Nandan and Reiner, 1997) via a mechanism involving Smad 
3 (Dong et al., 2001), whereas targeting of stromal cells and OBs by TGF-p 
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blunts BM production of IL-7 (Tang et al., 1997). Thus, TGF-P blocks T cell 
activation and T cell TNF production. Because the levels of TGF-p in bone 
and serum are increased by estrogen and blunted by ovx (Gray et al., 1989; 
Finkelman et al., 1992; Bord et al., 2001), TGF-P may be a pivotal upstream 
target of estrogen in bone as is suggested by estrogen failure to prevent bone 
loss in mice with a T cell-specific blockade of TGF-P signaling and complete in 
vivo prevention of ovx-induced bone loss by over expression of TGF-p (Yuhao 
Goa et al., 2004). However still, TGF-P and IFN-y have contradicting effects 
on bone metabolism. IFN-y signals through the Janus kinase-STAT pathway 
(Stark et al., 1998; Schindler and Darnell, 1995; Ihle JN., 1995) which is 
generally antagonistic to TGF-P signaling through SMADS-2 and -3 
(Massague J., 1998; Heldin et al., 1997) in the regulation of hemopoietic and 
immune-cell function (Letteria and Roberts., 1998; Ohta et al.,1987). TGF-p 
has been found to strongly promote TRAP-positive cell formation from 
mononuclear phagocyte precursors in response to TNF-a, whereas IFN-y 
primes these precursor cells for cytocidal macrophage activity (Ding et al., 
1988; Russell et al., 1977; Weinberg et al., 1978; Ruco and Meltzer, 1978) 
while inhibiting TRAP-positive cell formation. 
(c) Regulation of Glutathione / Thioredoxin and Glutathione Peroxidase 
Activity by Estrogen 
The physiological levels of estrogen are shown to maintain thiol antioxidants 
in rodent bone marrow as is evidenced by a substantial decrease in the level 
of glutathione and thioredoxin, the major tissue thiol antioxidants, and in the 
enzymes that regenerate their reduced forms in bone marrow of ovx-rats 
(Lean JM et al., 2003). Osteoclasts (Ocs), the bone resorbing cells, are 
identified as a target for the augmentation of oxidant-defense enzymes by 
estradiol thereby modulating ROS-sensitive pathways in OCs. Infact, OCs are 
a prime candidate for regulation of reactive oxygen species (ROS) since they 
express NADPH oxidase (Steinback et al., 1994), an enzyme capable of the 
cytokine-regulated generation of ROS during bone resorption (Garrett et al., 
1990). Besides, the activity of OCs is dependent upon several intracellular 
signals that are sensitive to ROS, including NF-kB, JNK, P13K, and p38MAP 
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kinase. ROS might also indirectly stimulate OCs by augmenting expression of 
resorptive cytokines such as IL-1, IL-6 and TNF-a that have been strongly 
implicated in E-deficiency bone loss (Jilka et al., 1992; Kitazawa et al., 1994; 
Roggia et al., 2001). Moreover, ROS and TNF-a not only stimulate resorption 
but also suppress osteoblastic differentiation (Mody et al., 2001; Gilbert et al., 
2002; Panagakos et al., 1996; Samoto et al., 2002). ROS may perturb 
osteoblastic function by inactivating nitric oxide (NO), deficiency of which is 
known to impair bone formation in vivo (Armour et al., 2001). 
The expression of glutathione peroxidase (GPx) activity, the major enzyme 
responsible for the intracellular degradation of hydrogen peroxide (H2O2), 
modulates the activity of osteoclasts (Ocs). Hydrogen peroxide (H2O2) has 
been shown to directly stimulate OC formation and function (Bax et al., 1992; 
Lean et al., 2003). Bone sparing activity of E has been linked to its ability to 
induce Gpx expression in OCs (Lean et al., 2004). Overexpression of Gpx in 
RAW cells has been shown to abrogate OC differentiation via a suppression 
of NFKB signaling pathway, which is ROS sensitive. Exposure of cells to 
H202 leads to the induction of expression of cytokines (IL-1, IL-6, TNF-a) 
implicated in E-deficiency bone loss (Kitazawa et al., 1994; Roggia et al., 
2001). H2O2 might also cause bone loss by up-regulation or down-regulation 
of the expression by bone cells of RANKL or ORG, or through the induction of 
apoptosis in osteoblastic cells (Kousteni et al., 2002). 
6. Role of Nitric Oxide (NO) in Bone Remodeling 
Nitric oxide (NO), an intracellular messenger stimulated by PTH and 1,25-
dihydroxyvitamin D3 have been known to exert complex effects on bone cells. 
Earliest studies have linked NO to bone remodeling whereby inhibition of NO 
synthase (NOS), the enzyme that synthesizes NO from L-arginine potentiated 
ovariectomised bone resorption in rats (Kasten et al., 1994). NO potently 
suppresses RANKL expression in both primary murine stromal cells and a 
stromal cell line, ST-2 while up-regulates OPG expression (Fan et al., 2004). 
Low concentrations of NO donors (SNP, NOR-4) have significant effects on 
both mRNA and protein levels of RANKL and OPG. Besides, NO, other 
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osteoactive factors are known to effect similar co-ordinate changes in RANKL 
and OPG expression like PTH and IGF-1 stimulates RANKL mRNA 
expression, while also decreasing OPG expression (Lee and Lorenzo., 2002; 
Rubin et al., 2002). TGF-(31, similar to NO, decreases RANKL while 
increasing OPG (Takai et al., 1998). Because of the universality of NO 
signaling, it may be that some of these factors regulate RANKL/OPG ratios 
through modulating NOS activity in bone cells. NO can influence their 
transcription through structural modifications of transcription factors, for 
instance changing the binding affinities of c-Fos, c-Jun, or NF-kB by S-
nitrosylation of cysteines near their DNA-binding domains (Marshall et al., 
2000; Nikitovic et al., 1998; Tidball et al., 1999). 
Nitric oxide is constitutively produced in osteoblasts (Obs) whereby it can be 
an effective mediator to regulate osteoblast (OB) proliferation and 
differentiation (O'Shaughnessy et al., 2000). However, over expression of 
NO leads to OB injuries (Damoulis and Hauschka, 1997; Mancini et al., 2000; 
Mogi et al., 1999). NO can damage osteoblast DNA and induce cell apoptosis 
(Chen et al., 2005). Besides, sodium nitroprusside (SNP), an NO donor, can 
decrease mitochondrial membrane potential of OBs consequently decreasing 
cellular ATP levels. SNP enhances release of intracellular ROS and 
cytochrome c from mitochondria to cytoplasm. Reduction of ATP synthesis 
(Blom et al., 2003) and enhancement of ROS (Mancini et al.,2000) induce cell 
apoptosis as is evidenced by suppression of Be! ?/Bax proteins following SNP 
treatment of OBs. Thus, the NO-induced death of osteoblastic cells has been 
shown to occur via an apoptotic pathway (Chen et al., 2005). 
7. Medicinally Important Compounds from Natural Sources Having Anti-
oxidant and Anti-inflammatory properties 
Natural antioxidants obtained from two different natural sources were 
employed in the present study involving modulation of bone markers at both 
the protein and gene levels in monocytes of postmenopausal osteoporotic 
patients. They were (a) allicin from garlic, and (b) neem extracts. The sole 
reason for selecting the above two natural antioxidants in the present study 
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was because of already proven beneficial effects at the molecular level by our 
laboratory in other disease systems (Hasan et a! 2006 and 2007). 
(a) Allicin 
Garlic [Allium sativum) is well known for its medicinal benefits and has been 
used in herbal medicine for thousands of years (Juszkiewicz et al., 2004). It 
has been cultivated since ancient times and used as a food, spice/condiment 
and folk remedy for many centuries (Rassoula e,. al., 2005). Garlic has a wide 
spectrum of pleiotropic actions, including antibacterial, antifungal and 
antioxidant activity. It is a strong antibacterial agent and acts as an inhibitor of 
both Gram-positive and Gram-negative bacteria (Ankri and Mirelman, 1999; 
Juszkiewicz et al., 2004). It also has beneficial effects on the cardiovascular 
and immune systems (Harris et al., 2001). During the past years, there has 
been a growing awareness of the potential medicinal uses of garlic. The 
antioxidant properties of garlic are well documented (Gedik et al., 2005; Sener 
et al., 2005). Garlic has been related to various vasoprotective and anti-
inflammatory effects (Borek, 2001; Sela et al., 2004). Garlic extracts can 
modulate the IL-1a-mediated cell response (adhesion) of human endothelial 
cells (Rassoula et al., 2005). Adhesion of mononuclear monocytes to 
endothelial cells and trans-endothelial migration of monocytes mediated by 
cell adhesion molecules (CAMs) are important steps in both inflammation and 
in the atherosclerotic process (Ikeda et al., 1998; Richter et al., 2003). 
Antioxidants act at the cellular level to downregulate cytokine-stimulated CAM 
expression in endothelial cells with a subsequent decrease in leukocyte 
adhesion (Zapolska-Downar et al., 2001). Since several components of garlic 
are known to possess antioxidant properties (Borek, 2001), garlic extract may 
be useful in reducing oxidative stress. Garlic oils stimulate the activity of 
glutathione peroxidase and inhibit the decreased ratio of reduced to oxidized 
glutathione produced by 12-0-tetradecanoylphorbol-13-acetate in epidermal 
cells (Perchellet et al., 1986). In addition, garlic extract was identified as a 
potent inhibitor of leukocyte migration (Hofbauer et al., 2001). 
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Ninety-five percent of the sulphur in intact garlic cloves is found in two classes 
of compounds in similar abundance: the S-alkylcysteine sulfoxides and y-
glutamyl-S-alylcysteines (Lawson, 1998). Upon cutting or crushing garlic 
cloves, odorless cysteine sulfoxides are very rapidly converted to a new class 
of compounds, the thiosulfinates, which are responsible for the odor of freshly 
chopped garlic. The most abundant sulphur compound in garlic is alliin (S-
allylcysteine sulfoxide) and the main thiosulfinate formed upon crushing garlic 
is allicin. The formation of thiosulfinates takes place when the cysteine 
sulfoxides, which are located only in the clove mesophyll storage cells, come 
in contact with the enzyme allinase or alliin lyase (E.G. 4.4.1.4.), which is 
located only in the vascular bundle sheath cells (Juszkiewicz et al., 2004; 
Chaverri etal., 2005). 
At the initial period of this reaction, pyruvate, ammonia and alk(en)yl sulfenic 
acid RS(0)H is formed; the latter undergoes rapid condensation to form 
thiosulfinates R-S(0)S-R, where R represents: methyl, 1-propenyl or 2-
propenyl group (Juszkiewicz et al., 2004). 
Allicin (diallyl thiosulfinate) is the major biologically active component and 
thiosulfinate compound of freshly crushed garlic. Garlic-rich organosulphur 
compounds and their precursors (allicin, diallyl sulfide and diallyl trisulfide) 
are believed to play a key role in the biological effects of garlic (Ankri and 
Mirelman, 1999). Garlic extract and S-allyl cysteine reduce hydrogen peroxide 
or TNF-induced NF-KB activation (Ide and Lau, 2001). Allicin was reported to 
affect different biological activities such as antimicrobial, antiparasitic and 
antifungal activities (Ross et al., 2001). Allicin has radical scavenging 
properties in activated granulocytes (Siegers et al., 1999) and may also inhibit 
inducible nitric oxide synthase expression in activated macrophages (Dirsch 
et al., 1998). The antimicrobial activity of allicin is considered to depend on its 
inhibitory effects on certain thiol-containing enzymes via strong SH-modifying 
properties, as reflected by the production of S-allylmercaptocysteine (Ankri 
and Mirelman, 1999; Rabinkov et al., 2000). Allicin freely permeates into or 
across phospholipid bilayers and interacts with the thiol groups of intracellular 
molecules (Miron et al., 2000). L-Cysteine of the antioxidant glutathione may 
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also be a target of allicin (Rabinkov et al., 2000). It has been found that allicin 
scavenges OH and Inhibits lipid peroxidation (Prasad et al., 1995). Higher 
doses (>100 pM) of allicin have proven toxic to mammalian cells. At present a 
variety of biological effects of allicin are attributed both to its SH-modifying 
and its antioxidant activity (Ankri et al., 1997). Although allicin, the active 
component of freshly crushed garlic, has different biological activities, 
however its anti-inflammatory properties warrant further investigation. Thus, 
we studied the incorporation of this herbal component as an anti-inflammatory 
agent for postmenopausal osteoporosis management. 
(b) Neem (Azadirachta indica) extract 
Azadirachta Indica A. Juss (syn. Melia Azadirachta) is well known in India and 
its neighboring countries for more than 2000 years as one of the most 
versatile medicinal plants having a wide spectrum of biological activity. Neem 
has been extensively used in alternative medicine i. e. ayurveda, unani and 
homoeopathic medicine and has become a cynosure of modern medicine. 
Since the early report by (Siddiqui, 1942) on the isolation of nimbin, the first 
bitter compound isolated from neem oil, more than 135 compounds has been 
isolated from different parts of neem. These compounds have been divided 
into two major classes: isoprenoids and others. The isoprenoids include 
diterpenoids and triterpenoids containing protomeliacins, limonoids, azadirone 
and its derivatives, gedunin and its derivatives, vilasinin type of compounds 
and Csecomeliacins such as nimbin, salanin and Azadirachta. The 
nonisoprenoids include proteins (amino acids) and carbohydrates 
(polysaccharides), sulphurous compounds, polyphenolics such as flavonoids 
and their glycosides, dihydrochalcone, coumarin and tannins, aliphatic 
compounds, etc. Although a large number of compounds have been isolated 
from various parts of neem, a few of them have been studied for biological 
activity. 
8. Aim of the present study 
The management of osteoporosis in postmenopausal (PM) women is poorly 
understood till date. Therefore, to better understand the pathogenesis of 
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estrogen deficiency bone loss, in the present study, a comparative 
characterization of sera and monocyte cultures derived from PBMC's of 
appreciable number of postmenopausal osteoporotic patients, 
postmenopausal non-porotic subjects, and premenopausal non-porotic 
healthy individuals has been undertaken with respect to measurement of 
activity of major antioxidant enzyme, namely glutathione peroxidase (GPx). 
Intramonocyte glutathione (GSH) and MDA levels were assessed for a 
parallel analysis of antioxidant power and lipid peroxidation. A comparative 
cytokine profile of sera and monocyte cultures with respect to IL-1(3 and TNF-
a by commercially available ELISA kit has been carried out in all three-study 
groups. Further, in this investigation, a comparative immunological evaluation 
was carried out for total characterization of PBMC cultures of above 
mentioned study groups with respect to TNF-a and ORG mRNA expression 
levels employing RT-PCR to focus on their respective roles. The modulation 
effects of natural herbal compounds— allicin and neem extract with respect to 
above parameters in culture supernatants and monocyte of all study groups 
have been examined. Toxicity assessment of both allicin and neem extract 
was done by assessing the effect on human housekeeping genes like (3- actin 
and 18SrRNA by RT-PCR. 
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Materials and Methods 
N-acetyl-cysteine, H2O2, SN50 (an inhibitor of NF-KB) and its analogue 
SN50/M, agarose, bovine serum albumin, Coomassie Brilliant Blue G-250 and 
R-250, p-nitrophenyl phosphate, anti-human IgG alkaline phosphate 
conjugate, Tween-20, dithiothreiotol, phenylmethyisulphonyl fluoride, standard 
protein markers, sodium azide, ethidium bromide, chloroform, isoamyl alcohol, 
reduced glutathione, glutathione reductase, cumene hydroperoxide and 
reduced (3-nicotinamide adenine dinucleotide phosphate were from Sigma 
Chemical Company, U.S.A. SN50 is a hybrid peptide containing nuclear 
localization sequence of p50 subunit of NF-KB heterodimer and has been 
shown to completely inhibit the translocation of NF-KB in human cell lines at 
100pg/ml(Linetal., 1995). 
Allicin was of LKT Laboratories, Inc. U.S.A. Ficoll-Paque was from Pharmacia, 
Piscataway, NJ, U.S.A. RPMI-1640 medium were from HiMedia, India. MTT 
cell viability assay kit and immunoassay kits for TNF-a and its receptors were 
from R & D Systems, U.S.A. 12-wells tissue culture plates were obtained from 
Techno Plastic Products (TPP), Switzerland. Polystyrene microtitre flat bottom 
ELISA plates having 96 wells (7 mm diameter) were from NUNC, Denmark. 
All other chemicals were of the highest analytical grade available. 
Study subjects: 
Venous blood was obtained from healthy nonsmoking adult female volunteers 
as well as from postmenopausal non-porotic (PM-NP) subjects and 
postmenopausal osteoporotic patients attending or admitted to the J.N. 
Medical College Hospital of A.M.U. Peripheral blood mononuclear cells 
(PBMCS') were isolated for further studies. Also, some portion of the blood 
collected was used for serum separation and stored at -20°C until required. 
Determination of protein concentration: 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford 
(1976). 
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(a) Protein estimation by the Lowry (Folin-Ciocalteau) method: 
Protein estimation by this method involves complexing of the protein's peptide 
bonds with Cu "^" under alkaline conditions (Lowry et al., 1951). The resultant 
Cu* appears to catalyze the oxidation of tyrosine and tryptophan residues by 
reducing phosphomolybdotungstate anions in the Foiin reagent (a mixture of 
sodium tungstate, molybdate and phosphate), added subsequently. This 
reaction develops a blue colour due to the formation of 
heteropolymolybdenum blue, which can be quantified by its absorbance at 
660 nm. 
Reagents: 
(i) Folin-Ciocalteau reagent 
The reagent was diluted 1:4 with distilled water L'=jfore use. 
(ii) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(a) 2% sodium carbonate in 100 mM NaOH 
(b) 0.5% copper sulphate in 1% sodium potassium tartarate 
The working reagent was prepared fresh before use by mixing the two 
components in the ratio 50:1, respectively. 
Procedure: 
To 1.0 ml of protein sample was added 5.0 ml of freshly prepared alkaline 
copper reagent. After thorough mixing, the reaction mixture was allowed to 
stand at room temperature for 10 minutes, followed by the addition of 1.0 ml 
of 1:4 times diluted Folin-Ciocalteau reagent. The contents were mixed 
immediately. The reaction was allowed to proceed for 30 minutes at room 
temperature and each tube was subsequently monitored at 660 nm. The 
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protein content of the unknown sample was determined by using bovine 
serum albumin to construct a standard calibration curve. 
(b) Protein estimation by the Bradford method: 
This method is based on strong binding of the dye Coomassie Brilliant Blue 
G-250, in acidic medium, to protein hydrophobically and at positively charged 
groups (Bradford, 1976). In the environment of these positively charged 
groups, protonation is suppressed and a blue color develops (Amax-595 nm). 
Preparation of dye: 
100 mg of Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% 
ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The 
resulting solution was diluted to a final volume of 1.0 litre and filtered through 
Whatman No. 1 filter paper to remove undissolved particles. 
Procedure: 
To 1.0 ml of solution containing 10-100 pg protein was added 5.0 ml of dye 
solution. The contents were mixed thoroughly by vortexing. The absorbance 
was read at 595 nm after 5 minutes against a reagent blank. 
Polyacrylamide gel electrophoresis of proteins: 
Polyacrylamide gel electrophoresis was performed under denaturing 
conditions as described by Laemmii (1970). 
Reagents: 
(i) Acrylamide-bisacrylamide (30 : 0.8) 
A stock solution of 30%) acrylamide containing 0.8% bisacrylamide was 
prepared by dissolving 30 gm of acrylamide and 0.8 gm of bisacrylamide in a 
total volume of 100 ml. The solution was stored at 4°C in an amber coloured 
bottle. 
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(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48 ml of 1 N 
HCI. The contents were mixed, pH adjusted to 8.8 and the final volume 
brought to 100 ml with distilled water. 
(iii) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with 
1 N HCI and the final volume adjusted to 100 ml with distilled water. 
(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled 
water, pH adjusted to 8.3 and the final volume made up to 1.0 litre with 
distilled water. 
(v) Sample buffer 
(a) 6.0 gm of Tris was dissolved in 80 ml distilled water and pH 
adjusted to 6.8 with phosphoric acid. The final volume was 
brought to 100 ml with distilled water. 
(b) 1.0 mg of bromophenol blue and 12.5 ml of glycerol were added to 
12.5 ml of the above solution. (3-mercaptoethanol was added just 
before use. 
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Recipe for 10-20% Gradient Gel 
Resolving Gel (total volume: 30 ml) 
Reagents 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10%SDS 
10% Ammonium persulphate 
TEMED 
10% 
5.0 ml 
3.8 ml 
150 pi 
50 pi 
10 pi 
20% 
10 ml 
3.8 ml 
150 pi 
50 pi 
10 pi 
The final volume was raised to 15 ml each with distilled water. 
2.5% Stacking Gel (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Stacking gel buffer 
10%SDS 
10% Ammonium persulphate 
TEMED 
0.8 ml 
2.5 ml 
100 pi 
75 pi 
25 pi 
The final volume was raised to 10 ml with distilled water. 
Recipe for 7.5% SDS-PAGE (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10%SDS 
10% Ammonium persulphate 
TEMED 
2.5 ml 
2.5 ml 
100 pi 
50 pi 
10 pi 
The final volume was raised to 10 ml with distilled water. 
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Procedure: 
The glass plates (18 cm x 16 cm) were soaked in chromic acid and thoroughly 
washed with tap water followed by a final rinse with distilled water and 
ethanol. The plates were dried and sealed with 1% agarose and 1.5 mm thick 
spacers. The reagents were mixed and poured between the glass plates. The 
resolving gel was allowed to polymerize at room temperature, following which, 
the stacking gel was layered on top. A well-forming comb was inserted 
immediately and the gel was left to polymerize at room temperature. In case 
of gradient gels, a gradient of resolving gel was formed with the help of a 
gradient former (Bio-Rad, model 385). After ensuring complete 
polymerization, the protein samples (25-100 pg) in one-fourth volume of 
sample buffer were electrophoresed at 80 volts at room temperature. The gels 
were stained using 0.25% Coomassie Brilliant Blue R-250 or with silver stain 
reagent. 
Silver staining: 
Silver staining was done by the method of Merril et al. (1983). Briefly, the gel 
was incubated in 40% methanol and 12% acetic acid for 45 minutes followed 
by incubation in 50% ethanol for 30 minutes. Next the gel was treated with 
0.02% hypo (sodium thiosulphate) for 1 minute. After washing with distilled 
water, the gel was placed in 0.2% silver nitrate (with 0.05% v/v formaldehyde), 
washed again with distilled water, and transferred to a 6% solution of sodium 
carbonate (with 0.05% v/v formaldehyde). After colour development, the gel 
was washed with distilled water and the reaction was arrested by treating the 
gel with 3% v/v acetic acid and 5% v/v methanol. All the reagents used in this 
procedure were freshly prepared. 
Agarose gel electrophoresis: 
Agarose gel was prepared by bringing 2% agarose to molten state in 
electrophoresis buffer (0.04 M Tris acetate, pH 8.0 containing 0.002 M EDTA). 
Molten agarose was poured on the gel tray and allowed to solidify for 1 hour 
at room temperature. The nucleic acid samples in one-tenth volume of stop-
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mix (30% ficoll, 0.025% xylene cyanole FF and 500 mM EDTA in 10X TAE 
buffer) were electropheresed for 2-4 hours at 30 mA in the same buffer. The 
gel was stained with ethidium bromide (0.5 |jg/ml). 
Enzyme-linked immunosorbent assay (ELISA): 
Antibodies were detected and quantified by ELISA using polystyrene flat-
bottom microtitre plates as solid phase. The method described by Alam and 
Ali (1992), Islam and Ali (1998) was followed for the assay. 
Buffers and reagents: 
(i) Tris-buffered saline (TBS) 
10 mM Tris, 150 mM NaCI, pH 7.4 
(ii) Tris-buffered saline Tween-20 (TBS-T) 
20 mM Tris, 144 mM NaCI, 2.68 mM KCI and 1.0 ml/litre Tween-20, 
pH7.4 
(iii) Bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6 
(iv) Substrate buffer (for anti-human IgG alkaline phosphatase conjugate) 
15 mM sodium carbonate, 35 mM sodium bicarbonate and 2 mM 
magnesium chloride, pH 9.6 
Substrate: 0.5 mg/ml of p-nitrophenyl phosphate 
(A) Direct binding ELISA: 
Polystyrene microtitre plates were incubated with 100 pi of protein antigen (30 
pg/ml in carbonate/bicarbonate buffer, pH 9.6) for two hours at room 
temperature followed by overnight incubation at 4°C. The plates were washed 
thrice with TBS-T and unoccupied sites blocked by 150 pi of BSA (1.5% in 
TBS, pH 7.4) for 4-6 hours at room temperature. Serially diluted sera in TBS 
were added to antigen-coated as well as control (antigen uncoated) wells. The 
antigen-antibody interaction was allowed to proceed for two hours at room 
temperature followed by overnight incubation at 4°C and subsequently the 
plates were washed four times with TBS-T in order to remove the unbound 
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antibodies. Bound antibodies were assayed by means of appropriate anti-
immunoglobulin alkaline phosphatase conjugate using p-NPP as 
substrate. The reaction was stopped with 3 N NaOH and the absorbance 
of each well was monitored at 405 nm on an ELISA microplate reader. 
Each sample was coated in duplicate and the results were expressed as a 
mean of Atest - Acontroi-
(B) Inhibition ELISA: 
The antigen binding specificity of antibody was determined by inhibition 
experiments (Hasan et al., 1991). Varying concentration of inhibitors (0-20 
|jg/mi) were mixed with a constant amount of antiserum or IgG. The mixture 
was incubated for two hours at 37°C followed by overnight incubation at 4°C. 
The resulting immune complex was employed in the immunoassay instead of 
serum. The rest of the steps were as in direct binding ELISA. The results were 
expressed as percent inhibition 
Percent Inhibition = . '^inhibited 
^uninhibited ) 
ATlOO 
Preparation of RPMI-1640 medium: 
Dehydrated RPMI-1640 medium of one unit via! (16.3 gm) was suspended in 
950 ml of tissue culture-grade water at room temperature with constant, 
gentle stirring until the medium was completely dissolved. The container was 
rinsed with tissue culture grade water to remove all traces of powder and 
added to the above solution. 3.7 gm sodium bicarbonate was added to the 
medium and stirred until dissolved. The final volume was brought to 1000 ml 
with tissue culture grade water. The medium was sterilized immediately by 
filtering through a sterile membrane filter with a porosity of 0.22 micron using 
positive pressure rather than vacuum to minimize the loss of carbon dioxide, 
and stored at 4°C till use. 
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Preparation of PBMC: 
Step 1: In order to isolate peripheral blood mononuclear cells (PBMCs), 60 ml 
of blood was drawn from a healthy volunteer into 60 cm^ syringes 
containing 3.8 units heparin/ml. The heparinized blood, in 15 ml 
aliquots, was transferred to sterile 50 ml polypropylene centrifuge 
tubes and diluted 1:1 with sterile 10 mM, PBS, pH 7.4 at room 
temperature, followed by gentle mixing by inverting the tube a few 
times. 
Step 2: Diluted blood was underlayered with 15 ml of Ficoll-Paque at room 
temperature using an 18 gauge spinal needle. Care was taken to 
prevent mixing of the layers. The gradient was centrifuged at 1800 rpm 
for 30 minutes at room temperature with the centrifuge brake turned 
off. 
Step 3: Using a sterile pipette, the upper clear layer containing plasma was 
removed. The PBMCs appeared as a dense white band (buffy layer) 
above the red blood cells and granulocytes layer. This was removed 
with another sterile pipette. The banded cells were combined in 10 ml 
aliquots. 
Step 4: Ten milliliters of banded PBMCs were diluted with 25 ml of PBS in 
sterile 50 ml polypropylene centrifuge tubes and centrifuged at 1100 
rpm for 12 minutes at room temperature to remove platelets, which 
remain in the supernatant. The PBMC pellets were combined to four 
tubes, diluted in 30 ml PBS and centrifuged at 1100 rpm for 10 
minutes at room temperature. This wash was repeated. 
Step 5: The pellets were then combined and resuspended in 30 ml complete 
medium (CM) (RPMI-1640 medium containing 2 M L-glutamine, 25 
mM HEPES, and no antibiotics). An aliquot was diluted 20-fold and 
counted using a hemocytometer under a light microscope using lOx 
ocular and 40x objective. 
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Preparation of autologous serum for monocyte culture: 
From the same donor, 30 ml of blood was drawn without anticoagulant and 
transferred to serum separator tubes. The blood was allowed to clot for at 
least 30 minutes, then centrifuged at 3000 rpm for 15 minutes at room 
temperature and the serum filtered through a sterile 0.22 pm filter unit. 
Autologous serum can be stored for a year or longer at -20°C. 
Cell culture: 
PBMCs (5x10^ cells/well) were added in 12-wells tissue culture plates in 
complete RPMI-1640 medium, and were subsequently incubated at 37°C, 5% 
CO2 for 1-2 hours for adherence. Thereafter, non-adherent cells were 
removed by washing the plates extensively 4 times with RPMI-1640 medium. 
The adherent monocytes were cultured in RPMI-1640 supplemented with 2% 
autologous serum, followed by overnight resting at 37°C, 5% CO2. This 
population of adherent cells is up to 95% monocytes, as observed by 
cytostaining and is 99% viable (Toossi et al., 1996). Prior to co-culturing with 
supplements, the plates were washed twice with RPMI-1640 medium. 
Co-culture of monocytes with supplements: 
Monocytes were adhered onto 12-well tissue culture plates and rested 
overnight as described above. Thereafter, as per experimental design, 
cultures, received 10 ng/ml varying doses of allicin (0-500 ng/ml), varying 
doses of reduced glutathione and N-acetyl-cysteine (NAG) (0-10 mM) 
respectively. Also, some cultures received 100 \iQlrx\\ SN50 and SN50/M. 
Cultures were then harvested after 24 hours and cells were lysed in 0.5 ml of 
TRIZOL Reagent (Invitrogen Inc. Carlsbad, CA, USA) or protein lysis buffer. 
The cell-free culture supematants were kept at -TCC. 
Treatment with allicin and monocytes viability assay: 
The effect of allicin (0-500 ng/ml) on the viability of monocytes was assessed 
by using MTT Cell Viability Assay Kit ( R & D Systems) according to the 
manufacture's Instructions provided. 
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Reagents supplied in the kit: 
Component 
MTT reagent 
Detergent reagent 
Quantity 
25 ml 
250 ml 
Storage conditions 
2-8°C 
18-24°C 
Assay procedure: 
Adherent monocytes were gently scraped with RPMI-1640 medium. After this, 
monocytes (3 x 10"* cells/well in 100 pi) were added in 96-well tissue culture 
plates. Cells were incubated in RPMI-1640 with 2% autologous serum 
containing allicin (50, 100, 250, and 500 ng/ml) or NAC (0-10 mM) for 24 hours 
at 37X, 5% CO2. After 24 hours, 10 \\\ of MTT reagent (3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was added to each well 
and incubation was continued for an additional two hours. When a purple 
precipitate was clearly visible under the microscope, 100 pi of detergent 
reagent was added to all wells, including control wells and incubated for two 
hours in the dark at 20°C. After incubation, the precipitate was solubilized and 
the absorbance of the resulting solution was measured at 570 nm using a 
microplate reader. Control cells were treated exactly the same except that no 
allicin was added to the wells. The percentage of viable cells was calculated by 
the formula as described by Islam et al. (2000) end the results are expressed 
as "Viable cells (% of control cells)". 
Viable monocytes (% of control cells) = ^bsorbancevalueof control cells ^^^^ 
A bsorbance value of treated cells 
Trypan blue exclusion assay for monocytes viability: 
Adherent monocytes were gently scraped with RPMI-1640 medium. Trypan 
blue suspension (1.6 mg/ml in saline solution) was added to the monocytes at 
a final concentration of 0.8 mg/ml. The cells were kept at 37°C for 7 minutes in 
a CO2 chamber (5%), mounted on a hemocytometer and then observed under 
light microscope. The cells taking up Trypan blue (dead cells), and cells 
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excluding the dye (viable cells) were counted. Percentage of viable cells was 
calculated by the following formula: 
% Cell viability ^ Total viable cells {mstaimd) ^^^^ 
Total cells {stained plus unstained) 
TNF-a Immunoassay: 
The concentration of TNF-a in various culture supernatants as well as in 
serum of pre-menopausal nonporotic subjects, postmenopausal non-porotic 
individuals as well as post menopausal osteoporotic patients was determined 
by use of a commercial ELISA Kit (R&D Systems). This assay employed the 
quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for TNF-a was available pre-coated onto a microplate. 
Standards and samples were pipetted into the wells and any soluble TNF-a 
present was bound by the immobilized antibody. After washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for TNF-
a was added to the wells. Following a wash to remove any unbound antibody-
enzyme reagent, a substrate solution was added to the wells and colour 
developed in proportion to the amount of TNF-a bound in the initial step. The 
colour development was stopped and the intensity of the colour was 
measured. 
Reagents supplied in the kit: 
TNF-a microplate - 96 well polystyrene microplate (12 strips of 8 wells) 
coated with a mouse monoclonal antibody against TNF-a. 
TNF-a conjugate - 21 ml of polyclonal antibody against TNF-a conjugated to 
horseradish peroxidase, with preservatives. 
TNF-a standard - 10 ng of recombinant human TNF-a in a buffered protein 
base with preservatives, lyophilrzed. 
Assay diluent RD1F - 6 ml of a buffered protein base with presen/atives. It 
contained a precipitate and was mixed well before and during use. 
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Calibrator diluent RD6-35 - 21 ml of animal serum with preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution of 
buffered surfactant with preservatives. 
Colour reagent A -12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B -12.5 ml of stabilized chromogen (tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Working reagents: 
Wash buffer - 20 ml of wash buffer concentrate was diluted into deionized or 
distilled water to prepare 500 ml of wash buffer. 
Diluted calibrator diluent RD6-35 - 20 ml of calibrator diluent RD6-35 was 
mixed with 80 ml of deionized or distilled water to yield 100 ml of diluted 
calibrator diluent RD6-35. 
Substrate solution - Colour reagents A and B were mixed together in equal 
volumes within 15 minutes of use to form substrate solution. It was protected 
from light. 
TNF-a standard - TNF-a standard was reconstituted with 1.0 ml of distilled 
water. This reconstitution produced a stock solution of 10,000 pg/ml. The 
standard was allowed to sit for a minimum of 15 minutes with gentle agitation 
prior to making dilutions. 
Assay procedure: 
50 \i\ of assay diluent RD1F was added to each well of 96 well 
polystyrene microplate coated with a mouse monoclonal antibody against 
TNF-a. Thereafter, 200 |jl of standards, samples, or control per well was 
added, covered with the adhesive strip piovided and incubated for 2 hours at 
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room temperature. The plate was washed four times by filling each well with 
wash buffer using a squirt bottle. After washing, 200 |jl of TNF-a conjugate 
was added to each well, covered with a new adhesive strip and incubated for 
1 hour for cell culture supematants and 2 hours for serum samples at room 
temperature. After four washings with wash buffer, 200 |jl of substrate solution 
was added to each well and incubated for 20 minutes at room temperature in 
the dark, a blue colour appeared. Thereafter, 50 pi of stop solution was added 
to each well to stop the reaction. Then the absorbance of each well was 
determined within 30 minutes, using a microplate reader set to 450 nm. The 
cut off or lower limit of sensitivity was 4.4 pg/ml. 
IL-1B Immunoassays 
The concentrations of soluble IL-1S in various culture supernatants were 
determined by use of commercial ELISA Kits (R&D Systems). 
Principle 
This assay employs the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for IL-1(3 has been pre-coated onto 
a microplate. Standards and samples are pipetted into the wells and any IL-1p 
present is bound by the immobilized antibody. After washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for IL-1(; 
is added to the wells. Following a wash to remove any unbound antibody-
enzyme reagent, an enhanced luminol/peroxide substrate solution is added to 
the wells and light is produced in proportion to the amount of IL-ip bound in 
the initial step. A microplate luminometer is used to measure the intensity of 
the light emitted. 
Reagents 
IL-1p Microplate: 96 well polystyrene microplate (12 strips of 8 wells) coated 
with a mouse monoclonal antibody against IL1p. 
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IL-ip Conjugate: 21 mL of polyclonal antibody against IL-ip conjugated to 
horseradish peroxidase, with preservatives 
IL-1p Standard: 25 ng of recombinant human IL-ip in a buffered protein 
base with preservatives, lyophilized 
Assay Diluent RD1W: 11 mL of a buffered protein base with preservatives 
Calibrator Diluent RD6-10 21 mL of a buffered protein base with 
preservatives 
Wash Buffer Concentrate: 100 mL of a 10-fold concentrated solution of 
buffered surfactant with preservatives 
Glo Reagent A: 4 mL of stabilized enhanced luminol 
Glo Reagent B- 8 mL of stabilized hydrogen peroxide 
Plate Covers: 4 adhesive strips 
Procedure. 
Bring all reagents and samples to room temperature before use It is 
recommended that all samples, standards, and controls be assayed in 
duplicate. 
1 Prepare all reagents, working standards, and samples as directed in the 
previous sections 
2 Remove excess microplate stnps from the plate frame, return them to the 
foil pouch containing the desiccant pack, reseal 
3 Add 100 uL of Assay Diluent RDIWto each well 
4 Add 100 uL of Standard, control, or sample* per well Cover with the 
adhesive strip provided Incubate for 2 hours at room temperature on a 
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horizontal orbital microplate shaker (0 12" orbit) set at 5000 rpm A plate 
layout IS provided to record standards and samples assayed 
5 Aspirate each well and wash, repeating the process three times for a total 
of four washes Wash by filling each well with Wash Buffer (400 |aL) using a 
squirt bottle, manifold dispenser or autowasher Complete removal of liquid at 
each step is essential to good performance After the last wash remove any 
remaining Wash Buffer by aspirating or decanting Invert the plate and blot it 
against clean paper towels 
6 Add 200 uL of IL-ip Conjugate to each well Cover with a new adhesive 
strip Incubate for 3 hours at room temperature on the shaker 
Note: Prepare Working Glo Reagent at this time 
7 Repeat the aspiration/wash as in step 5 
8 Add 100 uL of Working Glo Reagent to each well Incubate for 5 - 20 
minutes at room temperature on the benchtop Protect from light 
9 Determine the RLU of each well using a luminometer set with the following 
parameters 1 0 mm lag time, 0 5 sec/well read time, summation mode, auto 
gam on 
*Cell culture supernatant samples may require dilution 
Glutathione peroxidase assay: 
The activity of glutathione peroxidase (GPx) was measured as described 
elsewhere (IVIohandas et al., 1984; IVlates at a!., 1999). The oxidized 
glutathione (GSSG) produced during GPx reaction was immediately reduced 
by NADPH and glutathione reductase. Therefore, the rate of NADPH 
consumption was regarded as the rate of GSSG formation during the GPx 
reaction. Monocytes from patients and normal controls were co-cultured for 24 
hours with or without 10 mM NAG, 100 pg/ml SN50, 100 MQ/ml SN50/M and 
0-500 ng/ml allicin. Thereafter, cells were gently scraped with lysis buffer 
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containing protease inliibitors (50 mlVl Tris/HCI, pH 7.4; 1 mM EDTA; 500 mM 
PMSF). The cell suspension was homogenized with a sonicator on ice and 
centrifuged at 10,000 rpm for 10 minutes. Protein concentrations of 
supernatants were determined by the method of Bradford with BSA as the 
standard, and were subjected to GPx activity determination. The reaction 
mixture (1.0 ml) containing 50 mM potassium phosphate (pH 7.0), 1 mM 
sodium azide, 2 mM GSH, 0.2 mM NADPH, 1 unit/ml glutathione reductase, 
1.5 mM cumene hydroperoxide, and 20-100 pi of samples were incubated at 
25°C for 5 minutes. The reaction was initiated by the addition of cumene 
hydroperoxide. The kinetic change was spectrophotometrically recorded at 
340 nm (37°C) for 3 minutes. GPx activity was calculated after subtraction of 
the blank value, as pmol of NADPH oxidized/minute/mg protein (U/mg 
protein). 
Intramonocyte Glutathione Assay. 
Glutathione (GSH) levels in treated or control monocytes were assayed by 
spectrophotometry, using a GSH assay kit (Calbiochem) as previously 
described by us (Hasan et al., 2007 BBRC). Monocytes were mixed with 
equal volume of ice cold 5% metaphosphoric acid and centrifuged at 3000 
rpm for 15 min. Supernatants were used for GSH assay, as per the 
manufacturer's instruction. 
Assay for Malondialdehyde (MDA) levels. 
As a matter of fact, free radicals, because of their unstable and transient 
nature are difficult to measure directly. Their tendency to cause lipid 
peroxidation has been used as an indirect measure. Hence estimation of lipid 
peroxides (Markers of lipid peroxidation) was carried out by measuring MDA 
(Malondialdehyde) which is a stable end byproduct of lipid peroxidation. 
Principle: One Molecule of MDA reacts stoichiometrically with two molecules 
of thiobarbituric acid (TEA) at pH 3.5. The pink color chromogen can be 
measured spectrophotometrically at 532 nm. 
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Procedure: For assay 1 ml of serum was mixed with 2.5 ml of 20% 
trichloroacetic acid (TCA) and 1 ml of 0.67% of aqueous solution of TBA. The 
mixture was heated for 30 minutes in boiling water bath, the pink pigment was 
extracted with 2 ml of n-Butanol and its absorbance was read at 532 nm 
against n-butonol as blank : 
MDA= (OD of sample / OD of standard) x Concentration of standard MDA 
RNA extraction: 
After lysis of monocytes in 0.5 ml TRIZOL Reagent, the cell lysates collected 
in tubes were kept on ice and then 200 |jl of chloroform was added to each 
sample, followed by vortexing for 2 minutes, and centrifugation at 3000 rpm 
for 5 minutes. Samples were then transferred to fresh eppendorf tubes and 
centrifuged at 14,000 rpm for 15 minutes at 4°C. The aqueous layer was 
harvested and transferred to a fresh tube. After addition of 100 |jl Cleanascite 
(CPG Inc., Lincoln Park, NJ, USA), samples were gently rocked for 10 
minutes and then centrifuged at 14,000 rpm for one minute. The aqueous 
layer obtained was mixed with 500 \i\ of chloroform-isoamyl alcohol (24:1) and 
vortexed. RNA was precipitated using 50 pi of 1 M sodium acetate, and 475 pi 
of isopropanol at -20°C for 3 hours in the presence of glycogen. This was 
followed by centrifugation at 14,000 rpm and the pellet obtained was washed 
two times with 75% ethanoi, and resuspended in 87 pi DEPC-water. DNAase 
1 digestion (10 pi of 10X DNAse 1 buffer in 0.5 M Tris pH 7.5, 0.1 M MgCb, 1 
mM DTT; and 50 pg/ml BSA, 2.0 pi RNAase inhibitor; 10U RNAase free 
DNAase 1) was employed to remove DNA. The reaction was stopped by the 
addition of 700 pi of 0.5 M NH4OAC and the RNA was re-extracted using 500 
pi of acid phenol-chloroform (1:1). The aqueous layer was harvested, 
extracted again with chloroform-isoamyl alcohol and precipitated. 
Reverse transcriptase polymerase chain reaction (RT-PCR): 
The DNAase-treated RNA was subjected to reverse transcription using 
oligo(dT) primers with Superscript II reverse transcriptase (Invitrogen, Life 
Technologies, USA) according to the manufacturer's instructions. RNA (2 pg) 
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was transcribed into cDNA in a 20 |jl reaction volume containing 50 mM Tris-
HCI, pH 8.3, 75 mM KCI, 3 mM MgCIa, 10 mM DTT, 0.5 mM of each 
deoxynucleotide triphosphate, 25 |jg/ml oligo(dT)i2-i8 primers and 10 U/|jl of 
Superscript 11 reverse transcriptase, at 42°C for 50 minutes. The reaction was 
then stopped by heating at 70°C for 15 minutes followed by rapid chilling on 
ice. 
PCR: The primers used in the PCR are listed as under: 
cDNA for p-actin was amplified with various primer sets supplied by 
(Stratagene, La Jolla, CA, USA). For PCR, 2.0 pi of each cDNA sample was 
used as template in the PCR amplification. The reactions were carried out in a 
50 pi reaction volume containing 20 mM Tris-HCI, pH 8.4, 50 mM KCI, 1.5 mM 
MgCl2, 0.2 mM of each of the four dNTPs, 2U of Taq DNA polymerase 
(Invitrogen) and 0.2 pM of each forward and reverse primers. After initial 
denaturation for 2 minutes at 95°C, 35 cycles at 95°C for 15 seconds, 60°C 
for 45 seconds were performed, followed by 72°C for 1 minute. The reaction 
products were visualized by electrophoresis in 2% agarose after staining with 
0.5 pg/ml ethidium bromide. 
Quantitative real-time RT-PCR: 
Taqman technology i. e. real-time quantitative reverse transcriptase PCR (RT-
PCR), which is the latest innovation in the field of PCR technology, provides a 
sensitive, reproducible, and accurate method for determining mRNA levels in 
tissues or cells. The method is based on the detection of a fluorescent signal 
produced and monitored during the amplification process, without the need for 
post-PCR processing (Held et al., 1996). 
Two important findings led to the discovery of real-time PCR. First, the Taq 
polymerase has a 5'-3' exonuclease activity (Holland et al., 1991), apart from 
Its polymerase activity. Second, dual-labelled fluorogenic oligonucleotide 
probes have been created which emit a fluorescent signal only upon 
cleavage, based on the principle of fluorescence resonance energy transfer 
(Cardullo et al., 1988). In the TaqMan assay (Applied Biosystems, Foster City, 
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CA, USA), these two principles are combined. In this system a probe, the so-
called TaqMan probe, is designed to anneal to the target sequence between 
the classical forward and reverse primers. The probe is dually labelled, with a 
reporter fluorochrome (eg., 5-carbofluorescein, or FAM) at one end and a 
quencher dye (eg., N,N,N',N'-tetramethyl-6-carborhodamine, or TAMRA) at 
the other end. In the intact probe, the fluorescence emission of the reporter 
dye will be absorbed by the quencher dye. The probe will be degraded 
during the extension phase by the 5-3' exonuclease activity of the Taq 
polymerase, separating the reporter and quencher, thus resulting in an 
increase in reporter fluorescence emission. The amount of fluorescence 
released is directly proportional to the amount of product generated in each 
PCR cycle and thus can be applied as a quantitative measure of PCR product 
formation. 
Procedure: 
Internal fluorescent hybridization probes were used in ABI Prism 7700 
Detection System (ABI/PerkinElmer (PE) Biosystems, Foster City, CA, USA), 
which allows the sensitive and specific quantification of individual host (Hartel 
et al., 1999), RNA, transcripts (Wilkinson et al., 2001) by quantitative real-time 
RT-PCR. TaqMan™ PCR primers and probes as well as target-specific RT 
primer for each assay were designed as descrioed elsewhere (Wilkinson et 
al., 2001; Islam et al., 2004). The RT primers as well as primer and probe 
sequences used for host R18, TNF-alpha (Islam et al., 2004) and OPG 
(Nagasaw et al., 2002) have been previously reported. The primer and probe 
sequences were: 
R18 primer RT 
R18 primer R 
R18 primer F 
TNF-a primer RT 
TNF-a primer R 
TNF-a primer F 
OPG primer R 
OPG primer F 
5'-GACGGTATCTGATC-3', 
5'-CATTCTTGGCAAATGCTTTC-3', 
5'-CGCCGCTAGAGGTGAAATTC-3', 
5'-GGTTTCTACAACA-3', 
5'-GTTCGAGAAGATGATCTGACTGCC-3', 
5'-AGGCGGTGCTTGTTCCTCA-3', 
5'-GGGGACCACAATGAACAAGTTG-3', 
5'-AGCTTGCACCACTCCAAATCC-3', 
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All probes were dually labeled with FAM at the 5' end and TAMRA at the 3' 
end. The proximity of the dye (FAM) and the quencher (TAMRA) on the intact 
probe prevents detection of any fluorescence. However, degradation of the 
probe during the course of PCR allows the release and detection of FAM 
(Holland et al., 1991). The PCRs for all amplifications were similar: 5 }jl of 
each cDNA, 20 pi of Taqman Universal PCR Master Mix (PE Biosystems), 
which contains optimal amounts of AmpliTaq Gold DNA polymerase (which 
protects against amplicon carryover) and of dNTPs, and optimal amounts of 
probe and primers calibrated to allow measurement of the targets. First, cDNA 
was synthesized in the presence of 0.5 pi of murine leukemia virus enzyme 
(Invitrogen, USA)/reaction and 10 pM each RT primer, dNTPs, and other 
substrate. Conditions for PCR were similar for all products (1 cycle of 2 
minutes at 50°C and 1 cycle of 10 minutes at 95°C and then 40 cycles of 15 
seconds at 95°C and 1 minute at 60°C). The cycle threshold for each sample 
was compared with the cycle threshold values of known amounts of a 
standard DNA constructed for each target and amplified simultaneously. To 
assure lack of DNA contamination in the RNA samples, in some experiments, 
a duplicate tube of sample with no RT enzyme was included as control. DNA 
contamination remained negligible. In each sample, host 18S ribosomal RNA 
was used as the internal control. Expression of TNF-a mRNA as well as OPG 
mRNA was corrected to internal control (host 18S rRNA) in the same sample 
and was expressed as copies of TNF-a in 10^° copies of R18 (equivalent to 1 x 
10^ monocytes). 
Statistical analysis: 
Results were analyzed by paired t-test and the data expressed as mean ± 
SEM of six experiments unless otherwise specified. P<0.05 was considered 
statistically significant. 
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Results 
The present study involves comparative investigations on three categories of 
subjects, which includes (a) healthy subjects i. e. premenopausal non-porotic 
(Pre-M-NP), (b) postmenopausal non-porotic subjects (PM-NP) and (c) 
postmenopausal osteoporotic patients (PMOst). The data generated are from 
characterization and modulatory studies of healthy and patient's monocytes, 
PBMC's and serum. 
[A]: ANTIOXIDANT STUDY INVOLVING GPx ACTIVITY, 
INTRAMONOCYTE GLUTATHIONE AND MDA LEVELS: 
1. Determination of glutathione peroxidase (GPx) activity in serum of 
pre and postmenopausal osteoporotic patients. 
On account of high oxidative stress associated with postmenopausal 
osteoporosis, we first attempted to assess the anti-oxidant state of PMOst 
patients by determining the GPx activity in their sera. In comparison to the 
Pre-M-NP i.e., healthy subjects and PM-NP control subjects, the serum 
values of GPx activity in PMOst patients were significantly reduced. GPx 
activity in sera of PMOst patients, PM-NP control and Pre-M-NP healthy 
subjects was recorded as 41.78 U/ mg protein (P<0.001), 66.53 U/ mg protein 
(P<0.001) and 95.17 U/ mg protein (P<0.001) respectively (Fig. 1). All values 
represent mean ± SE of six experiments, p<0.001. 
2. Determination of glutathione peroxidasf^ (GPx) activity in culture 
supernatants of monocytes of pre and postmenopausal osteoporotic 
patients. 
Adherent monocytes from PBMC's of PMOst patients, PM-NP subjects and 
Pre-M-NP healthy individuals were cultured for 24 hours. Supernatants were 
then analyzed for GPx activity, which in PMOst patients was found to be 
suppressed by -'2.67-folds (33.88 U/ mg protein) when compared to that 
found in Pre-M-NP healthy subjects (73.5 U/ mg protein). Also, a significant 
suppression to the order of ~1.46-folds (50.08 U/ mg protein, P<0.001) was 
recorded in comparison to PM-NP subjects which served as control (Fig. 2). 
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Therefore, the results indicate that antioxidant defense system is 
compromised in women after menopause and more so with the incidence of 
osteoporosis. All values are mean ± SE of six experiments. 
3. Modulation of GPx activity in monocyte cultures by varying doses of 
allicin - a natural antioxidant from garlic. 
Taking into account the proven beneficial role of allicin (Allium sativum L) as a 
natural anti-oxidant from garlic, in a wide spectrum of pathological conditions, 
we opted to study its comparative effect on antioxidant state in 24 hours 
cultured monocytes from PMOst patients, PM-NP subjects and Pre-M-NP 
healthy individuals. 
Monocytes of all the three study groups were, therefore, co-cultured for 24 
hours with varying concentrations of allicin (0, 50, 100, 250, and 500ng/ml). 
Cultures were harvested and supernatants obtained were subjected to GPx 
activity determination. In case of PMOst patients, monocyte cultures devoid of 
any allicin exhibited a suppressed GPx activity (33.88 U/mg protein; P<0.001). 
On the contrary, the GPx activity was found to ameliorate by 1.27-folds (43.27 
U/mg protein; P<0.001), 1.53-folds (52 U/mg protein; P<0.001), 1.96-folds 
(66.5 U/mg protein; P<0.001) and 2.11-folds (71.58 U/mg protein; P<0.001) 
with 50 ng/ml, 100 ng/ml, 250 ng/ml and 500 ng/ml of allicin respectively (Fig. 
3). 
Similar observations, but of low magnitude, were observed in PM-NP subjects 
(Fig. 4) in comparison to the above PMOst patients. The GPx activity in 
cultures devoid of allicin was recorded as 50.08 U/mg protein (P<0.001), 
whereas monocyte cultures of PM-NP subjects receiving 50, 100, 250 and 
500 ngs/ml of allicin exhibited a dose-dependent GPx activities, which were of 
the order of 56.83 U/mg protein (P<0.001), 62.83 U/mg protein (P<0.001), 
70.13 U/mg protein (P<0.001) and 72.70 U/mg protein (P<0.001) respectively 
(Fig. 4). It is to be pointed out that insignificant variation in the activity; 74.17, 
76.63, 73.83, 75.38 and 76.27 U/mg protein was recorded for Pre-M-NP 
healthy individuals at all the above mentioned allicin concentrations (Fig. 5). 
These results clearly prove allicin as an effective natural antioxidant capable 
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of enhancing / ameliorating tine suppressed antioxidant state in case of 
postmenopausal osteoporosis. All values are mean ± SE, p<0.001 and n=6 in 
each study group. 
4. Dose response effect of neem extract on GPx activity in monocyte 
culture supernatants. 
Apart from exploiting the antioxidant properties of allicin from garlic, an attempt 
was also made to probe the comparative antioxidant/modulatory effects of 
neem extracts - a known herbal immuno-regulator and antioxidant, on GPx 
activities in monocyte culture of PMOst patients, PM-NP subjects and Pre-M-
NP healthy individuals. 
Monocytes of the above three groups were similarly co-cultured for 24 hours 
with varying doses of neem (0, 50,100, 250 and 500 pg/ml). GPx activity was 
found to progressively up-regulate / ameliorate in a dose-dependent manner 
in PMOst patients (Fig. 6). Thus, as evident from Fig. 6, monocyte cultures 
devoid of any neem extract exhibited a suppressed GPx activity (33.88 U/mg 
protein; P<0.001). On the contrary, the GPx activity was found to ameliorate 
by 1.43-folds (48.67 U/mg protein; P<0.001), 1.62-folds (54.97 U/mg protein; 
P<0.001), 2.06-folds (70.03 U/mg protein; P<0.001) and 2.19-folds (74.32 
U/mg protein; P<0.001) with 50 pg/ml, 100 pg/ml, 250 pg/ml and 500 [jg/ml of 
neem extract respectively (Fig. 6). 
Similarly, in case of PM-NP subjects, a dose-dependent effect of neem extract 
was observed. Thus, as evident from Fig. 7, the GPx activity in cultures 
devoid of neem extract was recorded as 50.08 U/mg protein (P<0.001), 
whereas monocyte cultures of receiving 50 pg/ml, 100 ijg/ml, 250 pg/ml, and 
500 pg/ml of neem extract exhibited a dose-dependent GPx activities, which 
were of the order of 52.93 U/mg protein (P<0.001), 70.59 U/mg protein 
(P<0.001), 74.28 U/mg protein (P<0.001) and 75.12 U/mg protein (P<0.001) 
respectively (Fig. 7). Moreover, insignificant variation in the GPx activities was 
recorded for Pre-M-NP healthy individuals at all the concentrations of neem 
extract (Fig. 8). Thus, as was the case with allicin as described above, the 
results here prove neem extract as an effective natural antioxidant capable of 
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raising / ameliorating the suppressed antioxidant state in case of 
postmenopausal osteoporosis. All values are mean ± SE, p<0.001 and n=6 in 
each study group. 
5. Determination of intramonocyte glutathione (GSH) levels. 
Further in-sight about high oxidative stress associated with postmenopausal 
osteoporosis was investigated by probing the intramonocye glutathione levels. 
Since glutathione (GSH) is a major tissue thiol antioxidant, its intramonocyte 
levels were investigated in 24 hours cultured monocyte supernatants of 
PMOst patients, PM-NP subjects and Pre-M-NP healthy individuals. As 
depicted in Fig 9, the levels of intramonocyte GSH were significantly reduced 
in PMOst patients (148.37pg/ml) by ~ 1.38-folds (205.05 pg/ml, P<0.001) 
~2.05-folds (304.70 pg/ml; P<0.001) in comparison to PM-NP subjects and 
Pre-M-NP healthy individuals respectively (Fig. 9). Thus, the results show that 
antioxidant defense declines in women after menopause and continues to 
decline further with the incidence of osteoporosis following menopause. All 
values are mean ± SE of six experiments; p<0.001. 
6. Allicin-induced modulation of intramonocyte glutathione (GSH) 
levels. 
Next, an attempt was made to probe for any positive modulatory / 
amelioration effect of varying doses of allicin (0, 50, 100, 250, and 500 ng/ml) 
on intramonocyte GSH levels in 24 hours monocyte cultures of all the above 
discussed three study groups. Substantially low level (148.37 pg/ml; P<0.001) 
of intramonocyte GSH was recorded at 0 ng/ml allicin or untreated PMOst 
patients' monocyte cultures compared to healthy Pre-M-NP individuals' 
monocyte cultures (304.70 pg/ml). An appreciable and dose-dependent up-
regulation of intramonocyte GSH levels through 169.02, 198.9, 265.25 to 
286.2 pg/ml was recorded for PMOst patients at 0, 50, 100, 250, and 500 
ng/ml allicin (Fig. 10). Similarly, the GSH levels increased dose-dependently 
in case of PM-NP subjects from 205.05 pg/ml through 220.15, 244.95, 280.58 
upto 292.67 pg/ml at above concentrations of allicin (Fig 11). However, 
insignificant variation was observed in case of Pre-M-NP healthy subjects; 
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304.70, 306.48, 302.50, 303.62 and 305.23 pg/ml (Fig 12). Therefore, allicin 
efficiently raised the depressed thiol anti-oxidant state in both the 
postmenopausal study subjects. All values are mean ± SE, p< 0.001 and n=6 
in each study group. 
7. Dose response effect of neem extract on intramonocyte glutathione 
(GSH) levels 
Also, effect of varying concentrations of neeni (0, 50, 100, 250, and 500 
pgs/ml) on intramonocyte GSH levels in 24 hour monocyte culture of all the 
three study groups was investigated. Again, significantly low levels of 
intramonocyte GSH were recorded at 0 pg/ml neem (148.37 pg/ml) in case of 
PMOst patients when compared to Pre-M-NP healthy subjects (304.70 pg/ml) 
and then increased dose-dependently through 162.90, 178.50, 253.90 to 
273.15 pg/ml at 50, 100, 250 and 500 pg/ml neem respectively (Fig 13). 
Similarly, values showed an up-regulation from 205.05 pg/ml through 216.25, 
246.33, 276.72 to 287.53 pg/ml in case of PM-NP subjects (Fig 14). While 
insignificant variation was observed in case of Pre-M-NP healthy subjects; 
304.70, 297.30, 303.13, 302.23 and 301.90 pg/ml at above mentioned doses 
of neem (Fig 15). Thus, neem can also be effectively used to improve the 
degenerating anti-oxidant state in the pathogenesis of postmenopausal 
osteoporosis. All values are mean ± SE, p<0.001 and n=6 in each of the three 
study groups. 
8. NFKB mediated suppression of Intramonocyte glutathione (GSH) 
levels In monocytes of patients with postmenopausal osteoporosis. 
Intracellular signaling via NFKB is known to be ROS sensitive and given the 
high oxidative stress in postmenopausal osteoporosis, monocytes from all the 
three study groups were co-cultured with 10 mM NAC, 100 pg/ml SN50, 100 
pg/ml SN50/M, 500 ng/ml allicin or 500 pg/ml neem for 24 hrs for comparative 
modulation of intramonocyte GSH levels. Control cultures (-) did not receive 
any treatment and revealed intramonocyte GSH levels of 304.70, 205.05 and 
148.37 pgs/ml (P<0.001 for all) for Pre-M-NP healthy individuals (Fig 16), PM-
NP subjects (Fig 17) and PMOst patients (Fig 18) respectively. At 24 hours. 
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NAC, a known anti-oxidant and SN50, an inhibitor of NFKB activation, both 
up-regulated the intramonocyte GSH levels in PMOst patients (243.67 and 
269.37 pgs/ml respectively; P<0.001 for all) as well as in PM-NP subjects 
(267.82 and 275.40 pg/ml respectively; P<0.001 for all). However, SN50/M, 
an inactive analogue of SN50, at same concentration, failed to cause any 
modulation either in PMOst patients or in PM-NP subjects (143.75 or 206.60 
pg/ml respectively). While allicin, a natural anti-oxidant; and neem, a herbal 
immuno-regulator chosen for this modulation study, both appreciably up-
regulated the intramonocyte GSH levels in PMOst patients (286.20 and 
273.15 pgs/ml respectively; P<0.001 for all) and PM-NP subjects (288.12 and 
281.00 pg/ml respectively; P<0.001 for all) much more potently than either 
NAC or SN50. Insignificant variation (304.70, 298.70, 300.15, 298.92, 302.40 
and 304.30 pgs/ml; P<0.001 for all) was recorded in case of Pre-M-NP 
healthy individuals with any of the modulating agent used here. These results 
collectively indicate that the down-regulated intramonocyte GSH levels in 
postmenopausal osteoporosis is NF-KB mediated, and that, allicin and neem 
both proved as potential natural and safer anti-oxidants in postmenopausal 
osteoporosis (Figs. 16-18). All values are mean ± SE, p<0.001 and n=6 in 
each of the study groups. 
9. Determination of serum IVIDA levels in pre- and post-menopausal 
palients. 
As a step further, following the results showing impaired antioxidant systems 
in PMOst patients as reflected above by decreased GPx activity and reduced 
GSH levels, we also measured the levels of a by-product of lipid peroxidation 
i.e., malondialdehyde (MDA) in the sera of PMOst patients to detect further 
signs of increased oxidative stress. In comparison to the Pre-M-NP healthy 
group (8.60 ng/ml), the serum MDA values were found to be almost three 
times higher in PMOst patients (23.37 ng/ml) and nearly two times higher 
when compared to the NP-PM control group (14.43 ng/ml) as depicted in Fig. 
19. All values are mean± SE of six experiments i.e., n=6 and p<0.001 in each 
case. 
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10. Determination of IVIDA levels in culture supernatants of monocytes. 
After determining the MDA levels in serum, an attempt was made to evaluate 
MDA levels in mononuclear phagocytes. Thus, adherent monocytes from 
PBMC's of all the above-mentioned three study groups were cultured for 24 
hours and supernatants analyzed for MDA levels, which in PMOst patients 
stood to a near three times (25.83 ng/ml) the level found in Pre-M-NP healthy 
group (7.28 ng/ml) and also significantly higher when compared to levels 
found in NP-PM subjects (15.19 ng/ml) as is evident in Fig. 20. Data represent 
mean ± SE of six experiments, p<0.001 in each case. Therefore, the MDA 
data indicates that postmenopausal osteoporotic women are indeed exposed 
to high oxidative stress as reflected by high levels of MDA both in serum as 
well as in supernatants of cultured monocytes of this particular group. 
11. Regulation of MDA levels in supernatants of cultured monocytes by 
natural antioxidants like allicin and neem extracts. 
Next, in order to find out allicin - a natural antioxidant from garlic, could prove 
beneficial in overcoming the raised oxidative stress so common in 
postmenopausal osteoporosis, monocytes obtained from all the three study 
groups were co-cultured for 24 hours with varying doses of allicin (0-500 
ng/ml) and supernatants compared for MDA levels. As is evident from Fig. 21, 
the MDA levels, ranging only from 7.28 ng/ml to 7.92 ng/ml in the 
supernatants of monocyte cultures of Pre-M-NP healthy subjects, remained 
more or less unaltered at all the concentrations of allicin used. On the 
contrary, in case of PMOst patients, the MDA levels showed a dose-
dependent decrease, which was of the order of 25.83, 18.21, 15.46, 10.49, 
and 8.01 ngs/ml when monocytes were co-cultured with 0, 50, 100, 250, and 
500 ngs/ml of allicin respectively (Fig. 23). Similarly, MDA levels decreased in 
a dose-dependent manner in NP-PM subjects from 15.19 ng/ml when no 
allicin was used to culture monocytes to 13.51, 10.29, 8.42, to 7.65 ngs/ml 
with 50, 100, 250, and 500 ngs/ml of allicin respectively (Fig. 22). Therefore, 
at doses of 250 and 500 ng/ml allicin, MDA levels in PMOst patients as well 
as NP-PM subjects were comparable to those found in Pre-M-NP healthy 
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subjects thereby upholding potential antioxidant property of allicin in 
combating high oxidative stress in postmenopausal osteoporosis. All values 
are mean ± SE, n=6 in each study group and p<0.001 in each case. 
Next, monocytes of all the three study groups were similarly treated for 24 
hours with varying doses of neem extract (0-500 pg/ml) to explore if any 
positive impact neem would show in the pathogenesis of postmenopausal 
bone loss. Thereafter, supernatants when analysed for MDA levels revealed a 
progressive down-regulation in PMOst patients from 25.83 ng/ml (in cultures 
devoid of neem extract) to 20.82, 16.82, 11.57 r.nd 9.93 ng/ml with 50, 100, 
250, and 500 pg /ml neem extract respectively as shown in Fig. 26. Similarly, 
in case of NP-PM subjects, MDA levels were 15.19 ng/ml in monocytes were 
cultures devoid of any neem extract. However, a dose-dependent suppression 
of the order of 14.44, 11.46, 9.18 and 8.30 ngs/ml was recorded with 50, 100, 
250, and 500 pg /ml of neem extract respectively (Fig. 25). Again as was the 
case with allicin, here also, no significant variation was observed at any of the 
above mentioned neem extract doses in case of Pre-M-NP healthy group with 
MDA levels exhibited as 7.28, 7.42, 7.39, 7.92, and 7.18 ng/ml respectively 
(Fig. 24). All values are mean ± SE of n=6 in each study group and p<0.001 in 
each case. Therefore, the MDA data substantiates that neem extract proved 
to be efficient antioxidant in postmenopausal osteoporosis. 
[B]: CYTOKINE STUDY 
1. Determination of IL-1P levels in sera and supernatants of monocyte 
cultures of PMOst patients, NP-PM subjects and Pre-M-NP healthy 
individuals by ELISA. 
Presence of high levels of pro-inflammatory cytokine IL-lp, an important bone 
marker, in postmenopausal osteoporosis is well established. Thus, an attempt 
was made to probe the levels of IL-lp in sera as well as monocyte culture 
supernatants of PMOst patients and results compared with those obtained 
from NP-PM subjects and Pre-M-NP healthy subjects. ELISA results depicted 
in Fig. 27, clearly show high basal levels of IL-lp in sera as well as monocyte 
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culture supernatants of PMOst patients (197.06 pg/ml and 163.86 pg/ml 
respectively) compared to IL-ip secretion in sera (37.23 pg/ml) and monocyte 
culture supernatants (28.46 pg/ml) of NP-PM subjects. While insignificant 
levels were detected in case of Pre-M-NP healthy individuals (6.19 pg/ml and 
5.41 pg/ml respectively). All values are mean ± SE; p<0.001 and n=8 in each 
study group. 
2. Dose-response effect of allicin on expression of IL-ip in monocyte 
culture supernatants. 
Monocytes of all the three study groups were cultured for 24 hours with 
varying concentrations of allicin (0, 50, 100, 250 and 500 ng/ml). Cultures 
were harvested and supernatants obtained were subjected to ELISA for 
comparative evaluation of IL-1|3 secretion. As is evident from Fig. 28, in 
comparison to control cultures devoid of any allicin (169.69 pg/ml; P<0.001), 
the expression of secreted IL-1(3 in PMOst patients was found to be down 
regulated by ~ 1.2-folds (140.46 pg/ml; P<0.001), 2.5-folds (67.59 pg/ml; 
P<0.001), 3.6-folds (47.17 pg/ml; P<0.001) and 5.04-folds (33.66 pg/ml; 
P<0.001) with 50, 100, 250 and 500 ngs/ml of allicin respectively. Similarly, in 
NP-PM subjects, IL-ip secretion was down regulated from 31.83 pg/ml at 0 
ng/ml allicin to 25.99, 22.35, 14.88 to 11.57 pgs/ml at 50, 100, 250 and 500 
ng/ml of allicin respectively (P<0.001 for all) (Fig. 29). In case of Pre-M-NP 
healthy subjects, low IL-ip secretion remained more or less unaffected; 5.61 
pg/ml, 5.18, 5.63, 4.56 and 4.78 pg/ml respectively at the above varying 
doses of allicin (Fig. 30). All values are mean ± SE, p<0.001 and n=6 in each 
of the three study groups. 
3. Dose-response effect of neem on expression of IL-1P in monocyte 
culture supernatants. 
Next, monocytes of all three-study groups i. e. Pre-M-NP healthy individuals, 
PM-NP subjects and PMOst patients were similarly treated with varying 
concentrations of neem extract (0, 50, 100, 250 and 500 pg/ml). A similar 
response was observed with neem as was observed with allicin In all the 
above-mentioned three groups. In case of PMOst patients, as is evident from 
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Fig. 31, in comparison to control cultures devoid of any neem >^ 
pg/ml; P<0.001), the expression of secreted IL-ip was found to, be down 
regulated by ~ 1.14-folds (151.68 pg/ml; P<0.001), 2.65-folds ( ^ 5 8 pgAril; 
P<0.001), 5.29-folds (32.89 pg/ml; P<0.001) and 7.05-folds ( 2 4 . 7 0 > ^ r 
P<0.001) with 50, 100, 250 and 500 pgs/ml of neem extract respectively (Fig. 
31). Next, IL-1(3 secretion was found to be dose-dependently decrease in NP-
PM subjects where the values obtained were 31.78, 27.96, 24.70, 21.66 and 
17.68 pgs/ml (Fig. 32; P<0.001 for all) at 0, 50, 100, 250, and 500 pg/ml neem 
extract respectively. While in Pre-M-NP healthy individuals, a very low or 
negligible IL-lp secretion to the order of 4.06, 5.35, 4.96, 4.36 and 4 19 
pgs/ml were recorded at the respective varying doses of neem extract (Fig 
33). All data represent mean ± SE; p<0.001 and n=6 in each of the three 
study groups. 
4. NF-KB mediated IL-1P suppression in monocyte culture supernatants. 
To compare the modulation in IL-ip secretion, monocytes were co-cultured 
separately with 10 mM NAC, 100 pg/ml SN50, 100 pg/ml SN50/M, 500 ng/ml 
allicin or 500 pg/ml neem extract. Control cultures (-) in each study group did 
not receive any treatment and the results revealed IL-ip basal levels of 5.27 
pg/ml, 31.78 pg/ml and 174.22 pg/ml in Pre-M-NP healthy subjects (Fig. 34), 
NP-PM subjects (Fig. 35) and PMOst patients (Fig. 36) respectively. Thus, as 
evident from Figs. 34-36, in comparison to Pre-IVI-NP healthy subjects, the 
basal levels of secreted IL-ip was found to be augmented by ~ 6.03-folds and 
~ 33.05-folds in monocyte culture supernatai^ts of NP-PM subjects and 
PMOst patients respectively. 
Next, modulatory studies revealed that, at 24 hrs, NAC, a known anti-oxidant 
and SN50 - an inhibitor of NFKB activation, both down-regulated the IL-ip 
secretion in PMOst patients as well as in NP-PM subjects. Thus, as illustrated 
in Fig. 35, NAC and SN50 suppressed the IL-ip expression by ~ 1.45-folds (i. 
e. from 31.78 to 21.90 pgs/ml; P<0.001) and -1.61-folds (i. e. from 31.78 to 
19.79 pgs/ml; P<0.001) respectively in NP-PM subjects. Next, analysis the 
data obtained revealed suppression in IL-ip expression by NAC and SN50 to 
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the order of ~ 3.34-folds (i. e. from 174.22 to 52.14 pgs/ml; P<0.001) and 
~4.04-folds (i. e. from 174.22 to 43.11 pgs/ml; P<0.001) respectively in PMOst 
patients (Fig. 36). On tlie contrary, SN50/M, an inactive analogue of SN50 
failed to show any modulation either in PMOst patients or NP-PM subjects 
(176.23 or 31.85 pg/ml respectively). While allicin, a natural anti-oxidant and 
neem, a herbal immuno-regulator respectively, chosen in this modulation 
study, both produced an appreciable down-regulation of IL-1|3 secretion in 
both PMOst patients (33.66 and 24.70 pg/ml respectively) and in NP-PM 
subjects (11.57 and 17.68 pg/ml respectively) much more effectively than 
either NAG or SN50. In case of Pre-M-NP healthy individuals insignificant 
variation was observed with any of the modulating agents. These results 
(Figs. 34-36) while indicating that the secretion of IL-1(3 is NF-KB mediated, 
prove efficacy of allicin and neem extract as natural and safer alternative or 
adjunct as anti-bone resorptive agents. All values are mean ± SE; p<0.001 
and n=6 in each study group. 
5. Dose-response effect of allicin on expression of secreted TNF-a 
proteins in monocyte culture supernatants. 
Next, after assessing the IL-ip levels, an attempt was made to probe the 
levels of secreted TNF-a proteins in monocyte cultures. Thus, adherent 
monocytes of all the three study groups were cultured for 24 hours with 
varying concentrations of allicin (0, 50, 100, 250 and 500 ng/ml). Cultures 
were harvested and supernatjants obtained were subjected to ELISA for 
comparative evaluation of TNF-a proteins secretion. As illustrated in Fig. 37, 
in comparison to control cultures devoid of any allicin (148.02 pg/ml; 
P<0.001), the expression of secreted TNF-a in PMOst patients was found to 
be down regulated by ~ 1.35-folds (108.96 pg/ml; P<0.001), 2.31-folds (64.09 
pg/ml; P<0.001), 4.57-folds (32.34 pg/ml; P<0.001) and 8.18-folds (18.08 
pg/ml; P<0.001) with 50, 100, 250 and 500 ngs/ml of allicin respectively (Fig. 
37). Similarly, in NP-PM subjects, TNF-a secretion was down regulated from 
48.50 pg/ml at 0 ng/ml allicin by around 1.37-folds (35.33 pg/ml), 2.36-folds 
(20.52 pg/ml), 3.91-folds (12.38 pg/ml) and 5.25-folds (9.23 pgs/ml) at 50, 
100, 250 and 500 ng/ml of allicin respectively (P<0.001 for all) (Fig. 38). In 
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case of Pre-M-NP healthy subjects, low TNF-a secretion remained more or 
less unaffected (Fig. 39). All values are mean ± SE, p<0.001 and n=6 in each 
of the three study groups. 
6. Dose-response effect of neem extract on expression of secreted TNF-
a proteins in monocyte culture supernatants. 
Thereafter, monocytes of all three-study groups i. e. Pre-M-NP healthy 
individuals, PM-NP subjects and PMOst patients were similarly treated with 
varying concentrations of neem extract (0, 50, 100, 250 and 500 pg/ml). A 
similar response was observed with neem as was observed above by allicin in 
all the above-mentioned three groups. In case of PMOst patients, as is 
evident from Fig. 40, in comparison to control cultures devoid of any neem 
extract (148.02 pg/ml; P<0.001), the expression of secreted TNF-a was found 
to be down regulated by - 1.25-folds (117.51 pg/ml; P<0.001), 4.11-folds 
(35.948 pg/ml; P<0.001), 4.97-folds (29.78 pg/ml; P<0.001) and 7.15-folds 
(20.69 pg/ml; P<0.001) with 50, 100, 250 and 500 pgs/ml of neem extract 
respectively (Fig. 40). Next, TNF-a secretion was found to be dose-
dependently decreased in NP-PM subjects where the values obtained were 
48.50 pg/ml, 37.29 pg/ml (1.3-folds), 27.20 pg/ml (1.7-folds), 16.54 pg/ml (2.9-
folds) and 11.90 pg/ml (4.1-folds) (Fig. 41; P<0.001 for all) at 0, 50, 100, 250, 
and 500 pg/ml neem extract respectively. While in Pre-M-NP healthy 
individuals, a very low or negligible TNF-a secretion was recorded at the 
respective varying doses of neem extract (Fig. 42). All data represent mean ± 
SE; p<0.001 and n=6 in each of the three study groups. 
7. NF-KB mediated secreted TNF-a protein suppression in monocyte 
culture supernatants. 
Further in-depth studies were carried out where comparable modulation in 
TNF-a secretion in monocytes that were co-cultured separately with 10 mM 
NAC, 100 pg/ml SN50 or 100 pg/ml SN50/M was probed. Control cultures (-) 
in each study group did not receive any treatment and the results revealed 
TNF-Q basal levels of 5.51 pg/ml, 48.50 pg/ml and 148.02 pg/ml in Pre-M-NP 
healthy subjects (Fig. 43), NP-PM subjects (Fig. 44) and PMOst patients (Fig. 
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45) respectively. Thus, as evident from Figs. 43-45, in comparison to Pre-IVl-
NP healthy subjects, the basal levels of secrel^d TNF-a were found to be 
augmented by ~ 8.64-folds and ~ 26.38-folds in monocyte culture 
supernatants of NP-PM subjects and PMOst patients respectively. 
Interestingly, modulatory studies revealed that, at 24 hrs, NAC, a known anti-
oxidant and SN50 - an inhibitor of NFKB activation, both down-regulated the 
TNF-a secretion in PMOst patients as well as in NP-PM subjects. Thus, as 
illustrated in Fig. 44, NAC and SN50 suppressed the TNF-a expression by ~ 
2.5-folds (i. e. from 48.5 to 18.9 pgs/ml; P<0.001) and ~2.7-folds (i. e. from 
48.5 to 17.92 pgs/ml; P<0.001) respectively in NP-PM subjects. Next, analysis 
the data obtained revealed suppression in TNF-a expression by NAC and 
SN50 to the order of ~ 4.6-folds (i. e. from 148.02 to 31.90 pgs/ml; P<0.001) 
and ~7.1-folds (i. e. from 148.02 to 20.76 pgs/ml; P<0.001) respectively in 
PMOst patients (Fig. 45). On the contrary, SN50/M, an inactive analogue of 
SN50 failed to show any modulation either in PMOst patients or NP-PM 
subjects. Insignificant variation was obtained in case of Pre-M-NP healthy 
subjects (Fig. 43).These results while indicate that the regulation of secreted 
TNF-a is NF-KB mediated, and that, it proves efficacy of allicin and neem 
extract as natural and safer alternative or adjunct as anti-bone resorptive 
agents. All values are mean ± SE; p<0.001 and n=6 in each study group. 
[C] STUDIES AT GENE LEVEL: 
1. Expression of basal TNF-alpha mRNA and ORG mRNA by quantitative 
•real-time' RT-PCR 
In this section, attempt has been made for comparative characterization of 
monocytes from PMOst patients, NP-PM subjects and Pre-M-NP healthy 
individuals with respect to TNF-a and OPG at the gene i. e. mRNA levels. 
PBMC's were isolated from the blood of above three study groups to obtain 
adherent monocytes as described in methods. Monocytes from PMOst 
patients were then subjected to TNF-a mRNA evaluation by real-time RT-PCR 
and compared with the values of TNF-a mRNA copy number recorded in 
monocytes from both the non-porotic premenopausal and postmenopausal 
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subjects. As is evident from Fig 46, in comparison to Pre-M-NP healthy 
subjects' monocytes, those from PMOst patients revealed the presence of 
high basal levels of TNF-a mRNA copy number which was to the order of 
8.84E+08 (p<0.001). Thus, in PMOst patients, TNF-a mRNA was ~ 7.4 logs 
(P<0.001) and 6.2 (P<0.001) logs higher than in Pre-M-NP and NP-PM 
subjects (Fig. 46). These data, therefore, revealed significantly high basal 
levels of TNF-a mRNA in the monocytes of PMOst patients. All values are 
mean ± SE of six experiments in each study group. 
- Next, monocytes from all the three study groups were subjected to OPG 
mRNA evaluation by real-time RT-PCR. In case of PMOst patients, the data 
obtained revealed higher basal levels of OPG mRNA copy number which was 
~ 9.1 logs (p<0.001) higher than the Pre-M-NP healthy subjects and ~ 6.1 
logs (p<0.001) than NP-PM subjects (Fig 47). The results therefore, indicated 
appreciably augmented basal levels of OPG mRNA in PMOst patients. 
2. Dose response effect of allicin and neem extract on human house 
keeping gene R18. 
In view of proven health benefits of garlic since ancient times as well as neem 
extracts having proven medicinal importance, we chose here to study action 
of allicin, an active component of garlic and also neem extract on monocytes 
isolated from PBMCs of the study groups. Thus, prior to any regulatory 
studies, an attempt was made to first probe the adverse effect of allicin as well 
as neem, if any, on the human house keeping gene R18. As evident from our 
results, neither allicin (0-500 ng/ml) (Fig. 48; P<0.001)) nor neem extract (0-
500 |jg/ml) (Fig. 49; P<0.001), had any significant adverse effect on the 
expression of human house keeping gene R18 rRNA at any of their respective 
concentrations as revealed by quantitative real-time RT-PCR. 
3. Dose response effect of allicin on TNF-a mRNA expression. 
Here, we first started with allicin to investigate its action upon TNF-a mRNA 
gene expression for which purpose adherent monocytes from PBMCs of 
PMOst patients, NP-PM and Pre-M-NP subjects were co-cultured with varying 
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concentrations of allicin (0-500 ng/ml) for 24 hours. Cultures devoid of any 
allicin served as control. Monocytes of all the three study groups were then 
subjected to TNF-a mRNA evaluation by real-time RT-PCR. It is evident from 
Fig 50, the expression of TNp-a mRNA showed dose-dependently down-
regulation in its copy number in case of PMOst patients. Thus, in comparison 
to cultures devoid of any allicin, the results exhibited a suppression in TNF-a 
mRNA expressions by ~ 0.6-logs (P<0.001), 3.4-logs (P<0.001), 5.3-logs 
(P<0.001) and 6-logs (P<0.001) with 50, 100, 250, and 500 ng/ml allicin 
respectively (Fig. 50). 
Likewise, expression of TNF-a mRNA was found to decrease appreciably in 
monocytes of NP-PM subjects by ~ 0.36 logs (P<0.001), ~ 0.8 logs (P<0.001), 
~ 1.3 logs (P<0.001) and ~ 2 logs (P<0.001) with 50, 100, 250 and 500 ngs/ml 
allicin respectively (Fig. 50). However, no significant expression or any 
variation was observed in case of Pre-M-NP healthy individuals (Fig. 50). The 
data in this experiment prove allicin as an effective natural suppressor of 
augmented TNF-a mRNA levels in postmenopausal osteoporosis whereby it 
can be used as a potent anti bone-resorptive agent in this kind of bone 
pathogenesis. Data represent mean ± SE of six experiments in each study 
group i.e., n=6 and p<0.001 in each case. 
4. Dose response effect of allicin on ORG mRNA expression. 
Allicin was also used to check its effect on OPG mRNA expression, therefore 
adherent monocytes from PBMCs of PMOst patients, NP-PM subjects, and 
Pre-M-NP healthy subjects were co-cultured with various doses of allicin (0-
500 ng/ml) for 24 hours. Monocytes of all the above three groups were 
subjected to OPG mRNA evaluation by real-time RT-PCR. As evident from 
Fig. 51, the expression of OPG mRNA showed dose-dependent 
downregulation with increasing doses of allicin used here. In case of PMOst 
patients, the OPG mRNA copy number was suppressed by ~ 0.4-logs 
(P<0.001), 3 -logs (P<0.001), 5.1-logs (P<0.001) and 6-logs (P<0.001) with 
50, 100, 250, and 500 ng/ml allicin respectively 
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Also, the copy number was found to decrease in monocytes of NP-PM 
subjects from 1.80E+03 when cultured alone. Varying doses of ailicin 
exhibited a suppression in OPG mRNA expression by ~ 0.7 logs (P<0.001), 
1.06 logs (P<0.001), ~ 1.8 logs (P<0.001) and ~ 2 logs (P<0.001) with 50, 
100, 250 and 500 ngs/mi ailicin respectively (Fig. 51). No significant change 
with these concentrations was observed in case of Pre-M-NP healthy 
individuals (Fig. 51). Data represent mean ± SE of six experiments (n=6) in 
each study group. 
5. Dose response effect of neem extract (NE) on TNF-a expression. 
Further, it was attempted to probe the effect of varying concentrations of 
neem extract (0-500 pg/ml) on the expression of TNF-a mRNA in 24 hour 
cultures of PBMCs isolated from PMOst patients, NP-PM subjects, and Pre-
M-NP healthy subjects. As depicted in Fig 52, monocytes when subjected to 
TNF-a mRNA evaluation by real- time RT-PCR showed dose-dependence on 
neem in all study groups. 
. As evident from Fig 52, the expression of TNF-a mRNA in PMOst patients 
was dose-dependently down regulated. Thus, in comparison to cultures 
devoid of any neem extract, the results exhibited a suppression in TNF-a 
mRNA expressions by ~ 0.14-logs (P<0.001), 3.07-logs (P<0.001), 5-logs 
(P<0.001) and 5.95-logs (P<0.001) with 50, 100, 250, and 500 pg/ml neem 
extract respectively (Fig. 52). 
Likewise, expression of TNF-a mRNA was found to decrease appreciably in 
monocytes of NP-PM subjects from 6.84E+02 when cultured alone, through ~ 
1.12 logs, -1.34 logs, 1.48 logs to 1.75 logs at 50, 100, 250, and 500 pg/ml 
neem extract (NE) co-culture respectively (Fig. 52). 
While no significant change in gene expression was observed in case of Pre-
M-NP healthy subjects at any of the concentrations of NE used (Fig. 52). The 
results are indicative that neem especially at 100, 250 and 500 pg/ml doses is 
effective natural regulators, and that, can be used against the pathogenesis of 
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.postmenopausal bone loss. All values are mean ± SE of six experiments 
(n=6). 
6. Dose response effect of neem extract (NE) on OPG mRNA expression 
Change in the expression of OPG mRNA with neem extract (NE) was also 
probed, whereby varying doses of NE (0-500 pg/ml) were used to co-culture 
the monocytes isolated from PBMCs of PMOst patients, NP-PM subjects, and 
Pre-M-NP healthy subjects for 24 hours. Monocytes were then subjected to 
OPG mRNA evaluation by real-time RT-PCR. As evident from Fig. 53, here as 
well, the expression of OPG mRNA showed dose-dependent downregulation 
with increasing concentrations of NE. In case of PMOst patients, the OPG 
mRNA copy number was recorded as 3.24E+09 when monocytes were 
cultured alone, thereafter a downregulation of as much as ~ 0.63 logs 
(P<0.001), 2.16 logs (P<0.001), ~ 4.2 logs (P<0.001) and 5.9 logs (P<0.001) 
was recorded at 50, 100, 250, and 500 \iglrc\\ neem respectively (Fig. 53) 
Also, neem extracts exhibited a dose-dependent suppression in OPG mRNA 
copy number in NP-PM monocytes from 1.80E+03 when cultured alone, 
through as much as -0.6 logs, ~0.96 logs, -1.7 logs to -2 logs at above neem 
concentrations (Fig. 53). No effect was recorded in case of Pre-M-NP subjects 
(Fig. 53). These results indicated that 100, 250 and 500 pg/ml NE significantly 
down-regulated the OPG mRNA expression in PMOst patients, moderately 
doing so in NP-PM subjects while non-significantly effecting the levels in Pre-
M-NP healthy individuals. All data are mean ± SE of six experiments 
6. Effect of 10mM NAC on TNF-a and OPG mRNA expression. 
Here, we used N-acetyl cysteine (NAC), which is a known anti-oxidant to 
effect the change in expression of TNF-a and OPG mRNA extracted from 
monocyte fraction of peripheral blood collected from PMOst patients. This was 
done in order to compare the effects as revealed by allicin and neem in our 
study on the expression of TNF-a and OPG mRNA in PMOst patient 
monocytes as described above. Therefore, monocytes were either treated or 
untreated with 10 mM NAC for 24 hours and then subjected to evaluation of 
TNF-a and OPG mRNA by real-time RT-PCR. As is evident in Fig 54, 
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untreated monocytes revealed higher expression of both TNF-a mRNA (~ 8.9 
logs; P<0.001) and OPG mRNA (~ 9.3 logs; P<0.001) in PMOst patients while 
treatment with 10 mM NAC caused a downregulation of ~ 5 logs (P<0.001) in 
TNF-a mRNA level and 4.76 logs (P<0.001) in OPG mRNA expression level 
in this study group (Fig. 54). While in previous results, allicin and neem have 
revealed more potent effect on both the genes expression. Data in this figure 
are mean ± SE of six individual experiments. 
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Fig 1: GPx activity in sera of premenopausal non-porotic (Pre-M-NP) healthy 
individuals, non-porotic postmenopausal (PM) and post-menopausal 
osteoporotic (PMOst) patients. Data represent mean ± SE of six experiments 
(P<0.001 for all). 
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Fig 2: GPx activity in supernatants of 24 hours cultured monocytes of 
premenopausal non-porotic (Pre-M-NP) healthy individuals, non-porotic 
postmenopausal (PM) subjects and postmenopausal osteoporotic (PMOst) 
patients. Data represent mean ± SE of six experiments (p<0.001). 
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Fig 3: Dose response effect of allicin on GPx activity in supernatants of 24 
hours cultured monocytes of postmenopausal osteoporotic patients. Varying 
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mean ± SE of six experiments (p< 0.001). 
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Fig 4: Dose response effect of ailicin on GPx activity in supernatants of 24 
hours cultured monocytes of non-porotic postmenopausal subjects. Varying 
doses of ailicin used here were 0, 50, 100, 250, and 500 ng/ml. Data are 
mean ± SE of six experiments (p< 0.001). 
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Fig 5: Dose response effect of allicin on GPx activity in supematants of 24 
hours cultured monocytes of premenopausal non-porotic healthy individuals. 
Varying concentrations of allicin used here were 0, 50, 100, 250, and 500 
ng/ml. Data are mean ± SE of six experiments (p<0.001). 
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Fig 6: Dose response effect of neem on GPx activity in supematants of 24 
hours cultured monocytes of postmenopausal osteoporotic patients. Varying 
doses of neem used here were 0, 50, 100, 250, and 500 pg/ml. Data are 
mean ± SE of six experiments (p<0.001). 
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Fig 7: Dose response effect of neem on GPx activity in supematants of 24 
hours cultured monocytes of non-porotic postmenopausal subjects. Varying 
doses of neem used here were 0, 50, 100, 250, and 500 pg/ml. Data are 
mean ± SE of six experiments (p<0.001). 
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Fig 8: Dose response effect of neem on GPx activity in supernatants of 24 
hours cultured monocytes of pre-menopausal non-porotic healthy individuals. 
Varying concentration of neem extract used here were 0, 50, 100, 250, and 
500 pg/ml. Data are mean ± SE of six experiments (p<0.001). 
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Fig 9: Intramonocyte GSH levels in supernatants of 24 hours cultured 
monocytes of premenopausal non-porotic (Pre-M-NP) healthy individuals, 
non-porotic postmenopausal (PM) subjects and postmenopausal osteoporotic 
(PMOst) patients. Data represent mean ± SE of six experiments (p<0.001). 
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Fig 10: Dose response effect of allicin on intramonocyte GSH level in 
postmenopausal osteoporotic patients (black bars). As another control, 
intramonocyte GSH levels were also determined for untreated pre-
menopausal non-porotic (Pre-M-NP) subjects (empty bars). Monocytes were 
cultured for 24 hours with varying doses of allicin i.e., 0, 50, 100, 250, and 500 
ngs/ml. Cultures were harvested and supernatants subjected to GSH level 
quantification by means of ELISA. Data are mean ± SE of six experiments 
(p<0.001). 
73 
Results 
a. 
o 
> 
I 
V) 
O 
0) 
>. 
o 
o 
c 
o 
E 
re 
[ Non-porotic postmenopausal subjects] 
400 
350 
300 
250 
200 
150 
100 
50 
0 
Pre-M- Ong 50 ng 100 250 500 
NP ng ng ng 
Concentration of allicin, ng/ml 
Fig 11: Dose response effect of allicin on intra-nonocyte GSH level in non-
porotic postmenopausal (NP-PM) subjects (black bars). As another control, 
intramonocyte GSH levels were also determined for untreated pre-
menopausal non-porotic (Pre-M-NP) subjects (empty bars). Monocytes were 
cultures for 24 hours with varying doses of allicin i.e., 0, 50, 100, 250, and 500 
ngs/ml. Cultures were harvested and supernatants subjected to GSH level 
quantification by means of ELISA. Data are mean ± SE of six experiments 
(p<0.001). 
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Fig 12: Dose response effect of allicin on intramonocyte levels of GSH in Pre-
M-NP healthy individuals. Monocytes were cultured for 24 hours with varying 
doses of allicin i.e., 0-, 50-, 100-, 250-, and 500 ng/ml. Cultures were 
harvested and supernatants subjected to GSH level quantification by means 
of ELISA. Data are mean ± SE of six experiments (p<0.001). 
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Fig 13: Dose response effect of neem extract on intramonocyte GSH 
level In postmenopausal osteoporotic patients (black bars). The control devoid 
of any neem extract was healthy pre-menopausal nonporotic cells (empty 
bars). Monocytes were cultured for 24 hours with varying doses of neem 
extract i.e., 0, 50, 100, 250, and 500 pg/ml. Cultures were harvested and 
supernatants subjected to GSH level quantification by means of ELISA. Data 
are mean ± SE of six experiments (p<0.001). 
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Fig 14: Dose response effect of neem extract on intramonocyte GSH level in 
non-porotic postmenopausal subjects (black bars). The healthy pre-
menopausal nonporotic cells were controls (empty bars). Monocytes were 
cultured for 24 hours with varying doses of neem extract i.e., 0, 50, 100, 250, 
and 500 |jg/ml. Cultures were harvested and supernatants subjected to GSH 
level quantification by means of ELISA. Data are mean ± SE of six 
experiments (p<0.001). 
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Fig 15: Dose response effect of neem on intramonocyte GSH level in 
premenopausal non-porotic healthy subjects. Monocytes were cultured for 24 
hours with varying doses of neem extract i.e., 0-, 50-, 100-, 250-, and 500 
|jg/ml. Cultures were harvested and supernatants subjected to GSH level 
quantification by means of ELISA. Data are mean ± SE of six experiments 
(p<0.001). 
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Fig 16: Modulation of intramonocyte GSH levels In premenopausal non-
porotic healthy subjects. Monocytes were cultured alone (-), and co-cultured 
with 10 mM NAC, or 100 pg/ml SN50, or 100 pg/ml SN50/M, or 500 ng/ml 
allicin, or 500 |jg/ml neem extract for 24 hours and harvested as described in 
methods. Supernatants were subjected to GSH level quantification by means 
of ELISA. Data are mean ± SE of six experiments (p<0.001). 
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Fig 17: Modulation of intramonocyte GSH levels in non-porotic 
postmenopausal subjects. Monocytes were cultured alone (-) and co-cultured 
with 10 mM NAC, or 100 pg/ml SN50, or 100 |jg/ml SN50/M, or 500 ng/ml 
allicin, or 500 pg/ml neem extract for 24 hours and harvested as described in 
methods. Supernatants were then subjected to GSH level quantification by 
means of ELISA. Data are mean ± SE of six experiments (p<0,001). 
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Fig 18: Modulation of intramonocyte GSH levels in postmenopausal 
osteoporotic patients. Monocytes were cultured alone (-) and co-cultured with 
10 mM NAC, or 100 pg/ml SN50, or 100 pg/ml SN50/M, or 500 ng/ml allicin, 
or 500 pg/ml neem extract for 24 hours and harvested as described in 
methods. Supernatants were subjected to GSH level quantification by means 
of ELISA. Data are mean ± SE of six experiments (p<0.001). 
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Fig 19: Levels of MDA in sera of premenopausal non-porotic (Pre-M-NP) 
healthy subjects, non-porotic postmenopausal (NP-PM) subjects, and 
postmenopausal osteoporotic (PMOst) patients. Data represent mean ± SE 
of six experiments i.e., n=6 in each study group (p<0.001). 
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Fig 20: Levels of MDA in supernatants of 24 hr cultured monocytes isolated 
from PBMCs of premenopausal non-porotic (Pre-M-NP) healthy individuals, 
non-porotic postmenopausal (NP-PM) subjects, and postmenopausal 
osteoporotic (PMOst) patients. Data represent mean ± SE of six experiments 
i.e., n=6 in each study group (p<0.001). 
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Fig 21: Dose response effect of allicin on MDA levels in supernatants of 24 
hr culture monocytes isolated from PBMCs of premenopausal non-porotic 
(Pre-M-NP) healthy individuals. Varying doses of allicin used here for 
monocyte co-culture were 0, 50, 100, 250, and 500 ng/ml. Data represent 
mean ± SE of six experiments i.e., n=6 and p<0,001 
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Fig 22: Dose response effect of allicin on MDA levels in supernatants of 24 
hr culture monocytes isolated from PBMCs of non-porotic postmenopausal 
(NP-PM) subjects. Varying doses of allicin used here were 0, 50, 100, 250, 
and 500 ng/ml. Data represent mean ± SE of six experiments i.e., n=6 and 
p<0.001. 
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Fig 23: Dose response effect of a\\\c\n on MDA levels in supernatants of 24 hr 
culture monocytes Isolated from PBMCs of postmenopausal osteoporotic 
(PMOst) patients. Varying doses of allicin used here were 0, 50, 100, 250, 
and 500 ng/ml. Data represent mean ± SE of six experiments i.e., n=6 and 
p<0.001. 
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Fig 24: Dose response effect of neem extract (NE) on MDA levels in 
supernatants of 24 hr culture monocytes isolated from PBMCs of 
premenopausal non-porotic (Pre-M-NP) healthy subjects. Varying doses of 
NE used to co-culture monocytes were 0, 50, 100, 250, and 500 pg/ml. Data 
represent mean ± SE of six experiments i.e., n=6 and p<0.001. 
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Fig 25: Dose response effect of neem extract (NE) on MDA levels In 
supernatants of 24 hr culture monocytes Isolated from PBMCs of non-porotIc 
postmenopausal (NP-PM) subjects. Varying doses of NE used here were 0, 
50, 100, 250, and 500 pg/ml. Data represent mean ± SE of six experiments 
i.e., n=6and p<0.001. 
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Fig 26: Dose response effect of neem extract (NE) on MDA levels in 
supernatants of 24 hr culture monocytes isolated from PBMCs of 
postmenopausal osteoporotic (PMOst) patients. Varying doses of NE used 
here were 0, 50, 100, 250, and 500 pg/ml. Data represent mean ± SE of six 
experiments i.e., n=6 and p<0.001. 
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Fig 27: Levels of IL-ip in supernatants of monocyte cultures and sera of 
premenopausal non-porotic (Pre-M-NP) healthy women, postmenopausal 
non-porotic (NP-PM) subjects, and postmenopausal osteoporotic (PMOst) 
patients. Data represent mean ± SE of eight experiments 
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Fig 28: Dose response effect of allicin on IL-1P secretion in supernatants of 
24 hrs cultured monocytes of postmenopausal osteoporotic patients. Varying 
doses of allicin used here were 0-, 50-, 100-, 250-, and 500 ng/ml. Data are 
mean ± SE of six experiments. 
91 
Results 
35 
30 
E 25 
c 20 
o 
o 
o 
(0 
iS 
o 
J3 
15 
10 
=! 5 
Non-porotic postmenopausal patients 
0 ng 50 ng 100 ng 250 ng 500 ng 
Concentration of allicin (ng/ml) 
Fig 29: Dose response effect of allicin on IL-1P secretion in supernatants of 
24 hrs cultured monocytes of non-porotic postmenopausal subjects. Varying 
doses of allicin used here were 0-, 50-, 100-, 250-, and 500 ng/ml. Data are 
mean ± SE of six experiments. 
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Fig 30: Dose response effect of allicin on IL-ip secretion in supernatants of 
24 hrs cultured monocytes of premenopausal non-porotic healthy individuals. 
Varying doses of allicin used here were 0, 50, 100, 250 and 500 ng/ml. Data 
are mean ± SE of six experiments. 
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Fig 31: Dose response effect of neem extract on 1L-1P secretion in 24 hrs 
cultured monocyte supernatants of postmenopausal osteoporotic patients. 
Varying doses of neem extract used here were 0-, 50-, 100-, 250-, and 500 
pg/ml. Data are mean ± SE of six experiments. 
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Fig 32: Dose response effect of neem extract on IL-ip secretion in 24 hrs 
cultured monocyte supernatants of postmenopausal non-porotic subjects. 
Varying closes of neem extract used here were 0-, 50-, 100-, 250-, and 500 
|jg/ml. Data represent mean ± SE of six experiments. 
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Fig 33: Dose response effect of neem extract on IL-ip secretion in 
supernatants of 24 hrs-cultured monocytes of premenopausal non-porotic 
healthy individuals. Varying doses of neem extract used here were 0-, 50-, 
100-, 250-, and 500 pg/ml. Data represent mean ± SE of six experiments. 
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Fig 34: Modulation of IL-1p secretion in 24 hrs monocyte culture supernatants 
of premenopausal non-porotic healthy individuals. Monocytes were cultured 
alone (-) and co-cultured with either 10 mM NAC or 100 MQ/ml SN50, or 100 
|jg/ml SN50/M or 500 ng/ml allicin or 500 |jg/nnl neem extract for 24 hrs and 
harvested as described in methods. Data represent mean ± SE of six 
experiments. 
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Fig 35: Modulation of IL-1(3 levels in 24 hrs monocyte culture supernatants of 
non- porotic postmenopausal subjects. Monocytes were cultured alone (-) and 
co-cultured with either 10mM NAC, or 100 pg/ml SN50, or 100 |jg/ml SN50/M, 
or 500 ng/ml allicin , or 500 pg/ml neem extract for 24 hrs and harvested as 
described in methods. Data represent mean ± SE of six experiments. 
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Fig 36: Modulation of IL-ip levels In 24 hrs nnonocyte culture supernatants of 
postmenopausal osteoporotic patients. Monocytes were cultured alone (-) and co-
cultured with either 10mM NAC, or 100 pg/ml SN50, or 100 |jg/ml SN50/M, or 500 
ng/ml allicin, or 500 pg/ml neem extract for 24 hrs and harvested as described in 
methods. Data are mean ± SE of six experiments. 
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Fig 37: ELISA for dose response effect of allicin on sTNF-alpha secretion In 
24 hr culture monocyte supernatants of postmenopausal osteoporotic 
patients. Varying doses of allicin used here were 0-, 50-, 100-, 250- and 500 
ng/ml. Data represent mean ± SE of six experiments. 
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Fig 38: ELISA for dose response effect of allicin on sTNF-alpha secretion in 24 hr 
culture monocyte supernatants of non-porotic postmenopausal subjects. Varying 
doses of allicin used here were 0-, 50-, 100-, 250- and 500 ng/ml. Data represent 
mean ± SE of six experiments. 
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Fig 39: ELISA for dose response effect of allicin on sTNF-alpha secretion in 24 hr 
culture monocyte supernatants of pre-menopausal non-porotic healthy subjects. 
Varying doses of allicin used here were 0-, 50-, 100-, 250- and 500 ng/ml. Data 
represent mean ± SE of six experiments. 
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Fig 40: ELISA for dose response effect of neem extract on sTNF-alpha 
secretion in 24hr culture monocyte supernatants of postmenopausal 
osteoporotic patients. Varying doses of neem extract used here were 0-,-50-, 
100-, 250- and 500 pg/ml. Data represent mean ± SE of six experiments. 
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Fig 41: ELISA for dose response effect of neem extract on sTNF-alpha 
secretion in 24 iir culture monocyte supernatants of non-porotic 
postmenopausal subjects. Varying doses of neem extract used here were 0-, 
50-, 100-, 250- and 500 pg/ml. Data represent mean ± SE of six experiments. 
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Fig 42: ELISA for dose response effect of neem extract on sTNF-alpha 
secretion in 24 hr culture monocyte supernatants of pre-menopausal non-
porotic healthy subjects. Varying doses of neem extract used here were 0-, 
50-, 100-, 250- and 500 pg/ml. Data represent mean ± SE of six experiments. 
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Fig 43: Modulation of sTNF-alpha in 24 hrs monocyte culture supernatants of 
pre-menopausal non-porotic healthy subjects. Monocytes were cultured alone 
(-) and co-cultured with either 10mM NAC, or 100 pg/mi SN50, or 100 pg/ml 
SN50/M for 24 hrs and harvested as described in methods. Data represent 
mean ± SE of six experiments. 
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Fig 44: Modulation of sTNF-alpha in 24 hrs monocyte culture supernatants of 
non-porotic postmenopausal subjects. Monocytes were cultured alone (-) and 
co-cultured with either 10mM NAC, or 100 pg/ml SN50, or 100 pg/ml SN50/M 
for 24 hrs and harvested as described in methods. Data represent mean ± SE 
of six experiments. 
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Fig 45: Modulation of sTNF-aipha in 24 hrs monocyte culture supernatants of 
postmenopausal osteoporotic patients. Monocytes were cultured alone (-) and 
co-cultured with either 10mM NAC, or 100 pg/ml SN50, or 100 |jg/ml SN50/M 
for 24 hrs and harvested as described in methods. Data represent mean ± SE 
of six experiments. 
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Fig, 46. 'Real time' RT-PCR for TNF-a mRNA expression in 24 hr cultures of 
PBMC's isolated from blood of (a) Pre-menopausal non-porotic subjects ( Pre-
M-NP; n=6, P<0.001), (b) Non-porotic Postmenopausal patients (NP-Post-M; 
n=6, P<0.001) and (c) Postmenopausal Osteoporotic patients (PM-0; n=6, 
P<0.001). 
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Fig. 47. 'Real time' RT-PCR for OPG mRNA expression in 24 hr cultures 
of PBMC's isolated from blood of (a) Pre-menopausal non-porotic subjects 
( Pre-M-NP; n=6, P<0.001), (b) Non-porotic Postmenopausal patients (NP-
Post-M; n=6, P<0.001) and (c) Postmenopausal Osteoporotic patients 
(PM-0; n=6, P<0.001). 
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Fig. 48. Dose response effect of allicin from garlic (0-500 ng/ml) assessed by 
'real time' RT-PCR for human house keeping gene R18 rRNA expression in 
24 hr cultures of PBMC's isolated from blood of (a) Pre-menopausal non-
porotic subjects (Pre-M-NP; n=6, P<0.001, empty bars), (b) Non-porotic 
Postmenopausal patients (NP-Post-M; n=6, P<0.001, black bars) and (c) 
Postmenopausal Osteoporotic patients (PM-O; n=6, P<0.001, square bars). 
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Fig. 49. Dose response effect neem extract (NE) (0-500 ug/ml) assessed by 
'real time' RT-PCR for human house keeping gene R18 rRNA expression in 
24 hr cultures of PBMC's isolated from blood of (a) Pre-menopausal non-
porotic subjects (Pre-M-NP; n=6, P<0.001, empty bars), (b) Non-porotic 
Postmenopausal patients (NP-Post-M; n=6, P<0.001, black bars) and (c) 
Postmenopausal Osteoporotic patients (PM-0; n=6, P<0.001, square bars). 
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Fig. 50. Dose response effect of allicin from garlic (0-500 ng/ml), assessed by 
'real time' RT-PCR for TNF-alpha mRNA expression In 24 hr cultures of 
PBMC's Isolated from blood of (a) Pre-menopausal non-porotic subjects ( Pre-
M-NP; n=6, P<0.001), (b) Non-porotIc Postmenopausal patients (NP-Post-M; 
n=6, P<0.001,) and (c) Postmenopausal Osteoporotic patients (PM-0; n=6, 
P<0.001). Allicin doses: 0 ng/ml (empty bars), 50 ng/ml (black bars), 100 
ng/ml (small square bars), 250 ng/ml (vertical line bars) and 500 ng/ml (ladder 
bars). 
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Fig. 51. Dose response effect allicin from garlic (0-500 ng/nni) assessed by 
'real time' RT-PCR for ORG mRNA expression in 24 hr cultures of PBMC's 
isolated from blood of (a) Pre-menopausal non-porotic subjects (Pre-M-NP; 
n=6, P<0.001, empty bars), (b) Non-porotic Postmenopausal patients (NP-
Post-M; n=6, P<0.001, black bars) and (c) Postmenopausal Osteoporotic 
patients (PM-O; n=6, P<0.001, square bars). 
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'real time' RT-PCR for TNF-alpha mRNA expression in 24 hr cultures of 
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M-NP; n=6, P<0.05, empty bars), (b) Non-porotic Postmenopausal patients 
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patients (PM-0; n=6, P<0.001, square bars). 
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n=6, P<0.05, empty bars), (b) Non-porotic Postmenopausal patients (NP-
Post-M; n=6, P<0.001, black bars) and (c) Postmenopausal Osteoporotic 
patients (PM-0; n=6, P<0.001, square bars). 
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Discussion 
Osteoporosis and its consequence of low trauma fracture constitute a major 
public health problem together representing an important cause of mortality 
and morbidity with annual incidence of fracture rates exceeding the combined 
incidence of breast cancer, stroke and heart attacks in postmenopausal 
women (PMW) incurring high health care costs. With the rapidly aging 
population, the absolute number of hip fractures, which are a major concern, 
is expected to increase from current 1.6 million to 4.5 million by the year 2050 
(Gulberg et a!., 1997). Furthermore, apart from the above, the seriousness of 
combating osteoporosis could be best seen from the fact that in advanced 
countries like United States of America, initiatives are being taken in the 
direction of Bone Health and Military Medical Readiness (BHMMR) Program 
in order to advance bone physiology research that leads to strategies to 
improve bone health of men and women in the military. 
It's a well established fact that due to augmented generation of reactive 
oxygen species (ROS) in vivo due to a wide spectrum of in-vivo-related 
reasons, leads to the activation, and in turn, up-regulation of bone markers 
like pro-inflammatory cytokine TNF-alpha and it's super family member 
osteoprotegrin (OPG) as well as osteopontin and calcitonin at both the protein 
and gene i. e. mRNA levels. This in turn results in accelerated osteoclast 
differentiation, thereby resulting for most chronic conditions that lead to loss of 
bone mass, including osteoporosis, arthritis, orthopedic implant loosening, 
etc. 
In view of the above, if ROS production in vivo is arrested or regulated, then 
the above-mentioned bone markers associated with chronic bone conditions 
could be easily regulated. As major treatments currently in use are being 
associated with many risk factors, thus, in the present study, attempts have 
been made to investigate the regulatory effects of natural antioxidants from 
herbals on human osteoclasts (OCs) generated from precursors obtained 
from standard peripheral blood samples of an appreciable number of 
osteoporosis subjects, which in turn, may help in developing novel therapeutic 
strategies to contain this emerging global epidemic. 
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Osteoporosis is a heterogeneous bone metabolic disorder associated with 
high cytol<ine production. Of many proinflammatory cytokines activated in 
postmenopausal (PM) osteoporosis, TNF-a is probably the dominant cytokine, 
which promotes osteoclastogenesis by augmenting the production of RANKL 
(Pfeilschifter et al 2002), the non-redundant cytokine responsible for 
osteoclast development (Hofbauer et al 2000). TNF-a is a pleiotropic cytokine, 
which at cellular level modulates a broad spectrum of responses, including 
inflammation, immunoregulation, proliferation, differentiation, and apoptosis 
(Ledgerwood et al., 1999) via its two cell surface receptors - TNFR1 and 
TNFR2. 
Osteoporosis represents a polygenic disorder that is largely modified by 
environmental, nutritional, and behavioral factors. Various candidate genes 
have been implicated to account for the genetic basis of osteoporosis, 
including hormones and their receptors, cytokines and growth factors, bone 
matrix proteins and others. Regulation of RANKL expression is key to the 
pathogenesis of many osteopenic disorders. Infact, the ratio of RANKL to its 
soluble, antiosteoclastogenic decoy receptor, OPG, is a reasonable indicator 
of the magnitude of systemic bone loss in these pathological conditions. In 
animal studies of knockout and transgenic mice, bone mass was positively 
correlated with the amount of the OPG gene product (Simonet et al., 1997; 
Bucay et al., 1998), thus suggesting that OPG and RANKL are obvious 
candidate genes for osteoporosis. Of interest, the promoter region of the 
human OPG gene (Morinaga et al., 1998) contains various binding sites that 
are able to mediate the stimulation of OPG gene expression by TGFp, BMP2, 
and the osteoblast-specific transcription factor Cbfal, or the inhibition by PTH 
.(Hofbauer and Heufelder, 2001). Both in vitro and in vivo models suggest that 
bone loss during estrogen deficiency is partly mediated by an up-regulation of 
RANKL and down-regulation of OPG (Hofbauer et al., 2000). Estrogen 
suppresses RANKL-induced osteoclast differentiation by different 
mechanisms (Shevde et al., 2000) and increases OPG expression and protein 
levels in human osteoblasts (Hofbauer et al., 1999). Furthermore, Ueland et 
al. (2003) found an age-related increase in the bone matrix accumulation of 
OPG in PMW, significantly negatively correlated with cortical bone mass. 
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Yano et al. (1999) suggested that the age-related increase in serum OPG was 
a compensatory response to increased osteoclastic resorption. Thus, 
although OPG is produced in many tissues, bone derived OPG may be 
released into circulation, and serum levels reflect the situation locally in bone. 
Besides, significantly higher OPG concentrations in PMW with osteoporosis 
and within the group still higher concentrations in women with lower BMD 
suggested that the concentration of OPG changes as a function of bone mass 
(Yanoetal., 1999). 
Another important cytokine, namely IL-1, is recognized for its potent effects on 
bone remodeling (Dinarello CA, 1991). IL-1 is known to inhibit bone formation 
in vitro (Stashenko et al., 1987) and in vivo (Nguyen et a!., 1991) and induces 
bone cells to secrete several other cytokines, which potentiate the effects of 
IL-1 in bone, such as IL-6 (Jilkaetal., 1992), 1L-11(Girasole et al., 1994), and 
M-CSF (Felix et al.,1989). Like TNF-a, IL-1 also promotes RANKL expression 
by marrow stromal cells and osteoblasts (Hofbaeur et al., 1999). Shi Wei et al. 
(2005) found that IL-1 substantially mediates TNF- induction of fRANKL 
expression by marrow stromal cells via enhanced expression of IL-1R1. Like 
TNF-a, IL-1 has the capacity to directly target mononuclear osteoclast 
precursors and promote their differentiation in presence of permissive levels 
of RANKL. Thus, IL-1 is a key downstream effector molecule in optimal TNF-
induced osteoclastogenesis. Furthermore, Kimble et al. (1995) showed that 
either block of IL-1 or TNF though decreases ovx-induced bone loss, 
complete prevention was only brought about by simultaneous block of both 
cytokines suggesting that osteoclastogenesis stimulated by IL-1, like TNF 
(Lam et al., 2000; Kitaura et al., 2004), is RANKL dependent. 
Although attenuation of biological activity of TNF-a has lately become an 
important therapeutic intervention in the management of a wide variety of a 
chronic inflammatory diseases (Shanahan and St Clair, 2002), concerns are 
raised since systemic anti-TNF therapy is attended by potentially fatal 
complications such as fungal infection and tuberculosis. Hence, much is to be 
gained by identifying the TNF-a responsive cells that mediate the cytokine's 
pathological properties with the aim of specific therapeutic targeting. 
120 
Discussion 
Therefore, our study involves the incorporation of conripounds from natural 
sources namely allicin in garlic and neem extract as natural herbal treatments 
for more efficient and relatively safer management of PM osteoporosis. 
Allicin (diallyl thiosulfinate) is the major biologically active thiosulfinate 
component of freshly crushed garlic. It has been shown to possess a broader 
range of bactericidal powers than penicillin (Koch and Lawson, 1996) and its 
antimicrobial activity is considered to depend on its inhibitory effects on 
certain thiol-containing enzymes via strong SH-modifying properties, as 
reflected by the production of S-ailylmercaptocysteine (Ankri and Mirelman, 
1999; Rabinkov et al, 2000). ESR and spin trapping technique demonstrated 
that allicin and its precursor, alliin (+S-ailyl-L-cysteine sulfoxide), possess 
significant antioxidant activity. In addition, it has been reported that allicin 
scavenges OH and inhibits lipid peroxidation (Prasad et al, 1995). 
Furthermore, experiments with human umbilical vein endothelial cells 
(HUVEC) show that garlic extract and S-allylcysteine reduce hydrogen 
peroxide or TNF-induced NFKB activation (Geng et al, 1997; Ide and Lau, 
2001). A more recent study proposed that the phytoestrogenic efficacy of an 
oil extract of garlic prevents ovarian hormone deficiency induced bone mineral 
loss possibly by promoting intestinal transference of calcium through the 
partial revival of the serum estrogen titer (Mukherjee et al, 2006). Neem 
(Azadirachta indica) is one of the most versatile medicinal plants having a 
wide spectrum of biological activity. Active compounds of the plant are mostly 
isoprenoids such as nimbidin, gedunin and vilasinin. Its different plant parts 
such as leaf, bark and neem oil extracts have multiple properties some of 
which include anti-inflammatory, antipyretic and analgesic activities. 
Immunostimulant activity of neem bark (Vander Nat et al., 1987) and oil 
(Upadhyay et al., 1992) has been reported. Aqueous neem leaf extract is 
known to have significant hypoglycemic effect (Chattopadhyay, 1999). Anti-
malarial (Khalid et al., 1986), anti-bacterial (Chopra et al., 1952) and anti-
fungal (Khan and Wassilew, 1987) properties of neem bark, leaf and oil 
extract have been detected. Furthemore, anticarcinogenic activity of neem 
leaf extract (Balasenthil et al., 1999) and antioxidant activity of neem seed 
extract has also been demonstrated (Rao et a\., 1998). 
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In the present study, we first undertook to characterize the sera from PMOst 
patients with respect to the predominant antioxidant enzyme, glutathione 
peroxidase (GPx). In a parallel way experiments, supernatants of cultured 
monocytes isolated from PBMC's of PMOst patients were similarly 
characterized whereby we found a remarkably reduced activity of this 
enzyme. Moreover, the levels of intramonocyte glutathione (GSH), a major 
non-enzymatic antioxidant, were significantly decreased in these patients. 
Further characterization of PMOst patient sera with respect to IL-1(3 level 
revealed much elevated secretion of this cytokine. Moreover, the levels of IL-
1(3 and TNF-a protein secretion in supernatants of 24 hr monocyte cultures of 
postmenopausal osteoporosis patients were found to be appreciably 
augmented. Real-time RT-PCR was employed to evaluate TNF-a and OPG 
mRNA expression and both were found to be elevated appreciably. 
Furthermore, sera as well as monocyte culture supernatants from such 
patients also exhibited appreciable levels of malondialdehyde (MDA), a by-
product of lipid peroxidation. The above observations were in accordance to 
earlier reports. 
After establishing a considerably low antioxidant power and the presence of 
high magnitude inflammatory cytokines, we examined the effectiveness of 
allicin and neem extract as natural pro-bone health compounds, focusing on 
their antioxidant activity as well as anti bone-resorptive activity so as to act as 
antagonists of postmenopausal bone loss. It is to be pointed out here that 
earlier reports employing higher concentrations of allicin have been shown to 
be toxic to host cells, whereas, our laboratory has proved lower allicin 
concentrations (0 - 500 ng/ml) to be non-toxic to host cells, thus in the 
present study, lower allicin doses were employed. The same is true with 
doses of neem extract. Thus, allicin as well as neem extract doses employed 
in our study, both of which proved to be non-toxic in our system of cells 
undertaken in this study as is evidenced by an insignificant effect on the 
expression of human house keeping gene R18. 
To the best of our knowledge, we report for the first time in monocyte culture 
system of postmenopausal osteoporosis patients, that both, allicin from garlic 
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as well as neem extract, (a) appreciably ameliorate the glutathione peroxidase 
(GPx) activity and intramonocyte glutathione (GSH) levels, (b) down-regulate 
the augmented MDA levels (c) appreciably down-regulate the expressions of 
bone markers like secreted TNF-a and IL-ip at the protein levels, and (d) 
significantly suppress the high magnitude augmented expressions of bone 
markers like TNF-a and osteoprotegerin (OPG) at the gene i. e., mRNA 
levels. These findings are discussed in the following paragraphs coupled with 
mechanism explanation involving NF-kB. 
ELISA results for the dose response studies clearly indicate up-regulation of 
GPx activity in the supernatants of cultured monocytes from PMOst patients 
when co-cultured with varying doses of allicin and neem extract. In a similar 
way, intramonocyte GSH levels were up regulated with these doses of allicin 
and neem extract. Further ELISA experiments were carried out to study the 
modulatory actions of a N-acetyl-cysteine (NAC) - a precursor of the in vivo 
antioxidant GSH, as well as of synthetic peptide, SN50 and its inactive 
analogue, SN50/M on the intramonocyte GSH levels in comparison to our 
selected natural compounds, allicin and neem extract. NAC addition although 
caused reversal of impaired oxidative neutralizing mechanisms, could not but 
match the effective antioxidant potential either of allicin or neem extract at 
doses used in our study. Moreover, the above results indicate the activation of 
intracellular signaling pathways especially NFKB that are known to be reactive 
oxygen species (ROS) sensitive, as is evident from SN50 and SN50/M 
studies. 
Next, ELISA experiments performed to assess the dose response effect of 
allicin and neem extract on the secretion of bone markers like TNF-a and IL-
1P in supernatants of cultured monocytes of PMOst patients clearly show 
significant down-regulation with increasing doses of both the test compounds. 
NAC and SN50 both showed highly inhibitory effects on TNF-a and IL-1p 
secretion while SN50/M failed to cause any effect. These finding reiterate the 
effectiveness of allicin and neem extract over NAC in alleviating conditions 
manifest in postmenopausal osteoporosis with respect to TNF-a and IL-ip 
production. 
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Secretion of cytokines TNF-a and IL-ip due to reactive oxygen species (ROS) 
were mediated through activation of NFKB, as is evidenced by their 
suppression in monocyte culture supernatants in the presence of SN50, an 
inhibitor of NFKB. On the contrary, SN50/M, an inactive analogue of SN50, 
failed to show any effect. It is known that ROS are potent inducers of 
resorptive cytokines such as TNF-a, IL-1, and IL-6 in many cells through 
activation of NFKB as is reported by Lean et al. (2003) whereby they found 
ROS similarly activated NFKB in osteoclasts. In view of it, our data 
demonstrate that this effect of SN50 involved inhibition of NFKB pathway 
induced by allicin and neem extract, probably by inhibiting the degradation of 
IKBQ. The NFKB heterodimer is retained in the cytoplasm in an inactive form 
through association with one of the IKBS inhibitory proteins. As a consequence 
of stimulation either directly or indirectly by TNF-a, IL-ip and ROS, IKBO is 
phosphorylated by a specific kinase complex (IKK) leading to its ubiquitination 
and subsequent proteolysis by the 28S proteosome (Lang et al, 2004; Li and 
Verma, 2002). The degradation of IKB releases active NFKB, which 
translocates to the nucleus and regulates gene expression by binding to KB 
binding sites or by interacting with other transcriptional factors (Brown et al, 
1995). Since a number of genes involved in inflammatory responses are 
regulated by NFKB pathway, thus a high magnitude down-regulation of NFKB 
pathway by allicin and neem extract would predictably reduce the elaboration 
of NFKB-mediated TNF-a and IL-1p secretion and also ROS generation by 
way of up-regulation of GPx activity and GSH levels. In addition, allicin and 
neem extract both exerted a higher degree of neutralizing effects than NAC 
on TNF-a or IL-ip secretion as well as in the up-regulation of GPx activity in 
monocyte cultures and intramonocyte GSH levels. 
The presence of augmented levels of TNF in the bone marrow of ovx animals 
and in the conditioned media of peripheral blood cells of post menopausal 
women (PMW) is well documented (Pacific! et al., 1991; Ralston SH, 1994; 
Kitazawa et al., 1994; Kimble et al., 1996; Ralston et a!., 1990; Shanker et al., 
1994). Moreover, the rationale for the use of monocytes in our study is 
justified for the fact that substantial fraction of monocyte/macrophage lineage 
has the potential to differentiate into osteoclastic cell phenotype — cells that 
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resorb bone. Recently, TNF-a was reported to be also able to induce 
osteoclastic cells from bone marrow macrophages in vitro (Kobayashi et al, 
2000). This ability of TNF-a to induce osteoclast-like cell formation through a 
direct effect on precursors might be the mechanism by which inflammation 
leads to osteolysis in diseases such as rheumatoid arthritis (Fox et al, 2000). 
TNF-a thus, being a major mediator of inflammation in bone, provides further 
aim to our study whereby, regulation of TNF-a by means of allicin and neem 
extract which being herbal compounds with acclaimed anti-inflammatory 
properties seems to lead to considerable improvement in the management of 
postmenopausal osteoporosis. 
A striking finding in the present study was also observed at the gene i. e. 
mRNA levels. We employed real-time RT-PCR to characterize monocytes of 
PMOst patients with respect to TNF-a and ORG mRNA and to focus on the 
relationship between their expressions in postmenopausal osteoporosis. In 
agreement with previous findings, our study also revealed elevated levels of 
TNF-a mRNA in PBMC cultures of PMOst patients. However, real-time RT-
PCR when employed to evaluate ORG mRNA expression revealed higher 
levels in these patients. The later result although concurrent to the earlier 
reports in humans is contrary to the findings in animal models. It has been 
difficult to demonstrate a role for ORG deficiency in the pathogenesis of 
osteoporosis, since ORG levels are not consistently altered. ORG levels 
increase with age, and it is possible that OPG production rises as a 
homeostatic response to limit the bone loss that occurs with an increase in 
other bone-resorbing factors (Khosia et al., 2004; Khosia et al., 2002). 
Moreover, it has been demonstrated that OPG expression is up regulated by 
TNFa and IL-ip besides other factors such as 1,25-dihydroxyvitamin D3 and 
BMP-2 (Hofbauer et al, 1998). This is consistent with our results where we 
found appreciably high levels of IL-1P as well as that of TNF-a. 
Thus, based on our findings of high levels of TNF-a and OPG gene 
expression, we probed the regulation of their gene expression in PBMC's of 
PMOst patients by allicin and neem extract. Since higher doses of allicin 
(>100 nM) have previously proven toxic (Ankri et al, 1997), cell viability and 
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potential cytotoxicity were determined for tlie lower concentrations employed 
in this study using trypan blue and MTT assays, where viability of -98-99% 
was observed (data not shown). Interestingly, no effect of either allicin or 
neem extract was observed on human housekeeping genes like R18, thereby 
demonstrating that the effect of allicin or that of neem extract was not 
mediated by cellular death, but rather by specific inhibition of TNF-a as well as 
of OPG mRNA expressions. 
Real-time RT-PCR results for the evaluation of dose response effect of allicin 
on mRNA expressions of TNF-a and OPG clearly indicate down-regulation of 
both these gene expressions in PBMC's of PMOst patients when co-cultured 
with varying doses of allicin therefore, clearly showing that allicin exerts potent 
anti-inflammatory effect on mononuclear cells of PMOst patient. A parallel 
dose response effect of neem extract was found on TNF-a and OPG mRNA 
expressions in PMOst PBMC's when varying doses of neem extract were 
used for co-culture therefore, pointing to neem extract especially at 250 and 
500 |jg/ml concentration as potent natural herbal immunoregulator that can be 
used efficiently against the pathogenesis of PM osteoporosis. NAG co-culture 
also down-regulated the TNF-d and OPG mRNA expressions, however, to a 
lesser extent than allicin and neem extract in our study thereby further 
indicating potential and beneficial use of these compounds in the 
pathogenesis of bone loss due to estrogen deficiency. 
Furthermore, evidence has accumulated that suggests that antioxidant 
deficiency has a negative impact on bone mass with several potential 
mechanisms underlying this relationship. For instance, NFKB, which is known 
to mediate some of the important actions of TNF-a, a cytokine synthesized in 
the bone microenvironment, on osteoclastogenesis, is activated in osteoblast-
like cells by mitogens and cytokine through the generation of ROI (lotsova et 
al., 1997; Schreck et al., 1991; Schreck et al., 1992; Sen and Packer et al., 
1996). In other words, intracellular free radical production might represent the 
final common mechanism of NFKB activation by a variety of factors 
(Kurochouchietal., 1998). 
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Recently, Jagger et al. (2004) found that GPx, the glutathione-dependent 
enzyme most effective in the degradation of hydrogen peroxide, is also the 
antioxidant enzyme that is most highly expressed by osteoclasts and its 
expression by osteoclasts is stimulated by estrogen, raising the likelihood of 
increased hydrogen peroxide concentration in the bone microenvironment 
following menopause. Further, a rise in hydrogen peroxide or a fall in thiol 
antioxidants following a decline in estrogen essentially recruits TNF-a for the 
induction of bone loss (Jagger et al., 2005). Estrogen deficiency has also 
been reported to cause bone loss through increased expression of other 
cytokines such as IL-1 and IL-6 in supportive bone marrow cells and in 
monocytes and lymphocytes (Manologas et al., 2002; Pfeilschifter et al., 
2002). 
Therefore, ELISA experiments that we conducted to further detect signs of 
increased oxidative stress in PMOst patients by way of measurement of MDA 
levels attested to the fact that these patients are indeed exposed to greater 
oxidative stress levels. Next, ELISA results for the dose response effect of 
allicin and neem extract again indicated significant down-regulation of MDA 
levels of about 31% and 38% in supernatants of monocyte cultures of PMOst 
patients when these were co-cultured with varying doses of allicin and neem 
extract respectively. There is substantial likelihood that the subsequent 
increase in hydrogen peroxide levels due to depressed GSH and GPx activity 
in PMOst patients, might have induced the peroxidation of polyunsaturated 
fatty acids and lead to the formation of high MDA levels. Since MDA has got 
high reactivity towards amino groups, it inhibits the synthesis of nucleic acids 
and proteins and also deactivates the enzymes (Bird et al., 1980). 
Thus, in summary, the present study shows that postmenopausal 
osteoporosis exposes women to high oxidant stress whereby estrogen 
deficiency creates a vicious cycle of inflammation which together with 
presence of excess ROS complement one another to cause bone 
microarchitectural damage. Our study demonstrates appreciable reversal of 
neutralizing mechanisms by allicin and neem extract, which correlates 
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inversely with tine down-regulation of TNF-a, IL-1P and OPG mRNA 
expression in monocytes of PMOst patients. 
In conclusion, it can be inferred fronn the present study that: 
1. There is significant suppression of GPx activity both in sera as well as 
in monocyte cultures of PMOst patients. Furthermore, intramonocyte 
GSH levels also show significant down-regulation in such patients. 
2. Allicin and neem extract both dose-dependently up-regulate/ 
ameliorate the suppressed GPx activity as well as GSH levels. 
3. Activation of monocytes by ROS induces augmented basal levels of 
TNF-a and IL-1P secretion, both in sera as well as in monocyte cultures 
of PMOst patients. 
4. Allicin and neem extract both efficiently cause down-regulation in the 
TNF-a and IL-1|3 secretion in a dose-dependent manner. 
5. There is high expression of TNF-a and OPG mRNA in the PBMC's of 
PMOst patients. 
6. 500-ng/ml allicin and 500-pg/ml neem extract exhibited no toxic effect 
on the viability of human housekeeping gene R18. 
7. Allicin and neem extract dose-dependently down-regulated the 
expression of both TNF-a and OPG mRNA in PBMC cultures. 
8. Significantly high MDA levels were seen in both sera as well as in 
monocyte cultures of PMOst patients. 
9. Allicin and neem extract dose-dependently down-regulated the MDA 
levels in monocyte cultures. 
10. Allicin and neem extract both exhibited potential antioxidant as well as 
anti- bone resorptive properties as suggested from results observed 
from down-regulation of bone markers like TNF-a, 1L-1P and OPG. 
Thus, in summary, based on the results, it is hoped the present study would 
be of immense help in the better understanding of osteoporosis / post-
menopausal osteoporosis management by employing natural antioxidants. 
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